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Chondrosarcoma is a malignant cartilage-forming neoplasm and the second most frequent 
primary bone sarcoma, representing approximately 25% of all primary bone cancers. Evidence 
suggests that conventional chondrosarcoma arises from pre-existing benign lesions in the 
bones. Despite the huge efforts done for the better understanding of this malignancy, there is 
still a big gap in knowledge regarding the etiology of these tumors and the genes involved in 
chondrosarcoma progression. Chondrosarcoma is associated with two major clinical 
challenges. First, these tumors are highly resistant to conventional chemo- and 
radiotherapeutic regimens, leaving surgical resection of tumors as the only available curative 
treatment. Consequently, efficient therapeutic options for patients with recurrent, metastatic or 
inoperable tumors are absent. Therefore, patients with advanced disease face a poor prognosis. 
The second challenge influencing the decision making is the current dismal accuracy for 
radiological and histopathological diagnostic assessment. Due to the lack of tumor-specific 
biomarkers, it is very arduous to discriminate chondrosarcoma tumors of different grades, and 
even to distinguish them from other tumors of the cartilage.   
Thus, it is essential to expand the understanding of the genetic drivers involved in 
chondrosarcomagenesis and cancer progression. Unraveling the molecular factors contributing 
to chondrosarcoma pathophysiology will open up the possibility to develop targeted therapies, 
which may eventually improve the current clinical management and improve patients’ survival 
rates. Additionally, novel molecules could also serve as diagnostic biomarkers that facilitate 
the distinction of chondrosarcoma tumor subtypes. 
In order to contribute to the improvement of this defiant scenario, the research presented in 
this thesis focused on elucidating deregulated microRNAs (miRNAs) that are relevant for 
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chondrosarcoma pathogenesis. miRNAs are a family of small non-coding RNAs of 
approximately 20-22 nucleotides in length. They participate in a wide variety of biological 
processes through posttranscriptional regulation of gene expression. They play an essential 
role in cancer progression and uncovering their biological contribution and gene targets has 
great utility. Additionally, considering their origin-specificity and high stability in body fluids, 
we sought to also test the potential of candidate miRNAs as non-invasive biomarkers. 
In summary, the results demonstrated here show that two deregulated miRNAs (miR-
143/145) inversely correlate with tumor grade and play a key tumor suppressor role in 
chondrosarcoma in vitro and in vivo. Additionally, a combined in silico/sequencing approach 
revealed fascin-1 (FSCN1) as a direct target of miR-143/145, and its depletion phenotypically 
resembled miR-143/145 upregulation in vitro. We could demonstrate that FSCN1 
overexpression is commonly found in high-grade chondrosarcoma tumors, and it contributes 
to the malignant phenotype of chondrosarcoma cells. Last but not least, miR-143/145 was also 
shown to be deregulated in plasma samples from chondrosarcoma patients. Importantly, 
circulating miR-145 levels can discriminate with a high accuracy between different cartilage 












2HG    d-2-hydroxyglutarate 
αKG   α-ketoglutarate 
AGO   Argonaut 
AKT  Protein kinase B 
ATP  Adenosine triphosphate 
BCL-2  B-cell lymphoma 2 
CD(n#)+ Cluster of differentiation + number 
COX-2 Cyclooxygenase-2 
CTC  Circulating tumor cell 
Dox  Doxycycline 
EDTA  Ethylenediaminetetraacetic acid 
EMC  Extracellular matrix components 
EMT  Epithelial-mesenchymal transition 
EV  Empty vector 
EZH2  Enhancer of zeste 2 polycomb repressive complex 2 
FAM13A  Family with sequence similarity 13 member A 
FSCN1 Fascin-1 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GOLM1 Golgi membrane protein 1 
HDAC  Histone deacetylases 
HDL  High-density lipoproteins 
HELLS Helicase, lymphoid-specific 
HIF-1α  Hypoxia inducible factor-1α 
HLA  Human leukocyte antigen 
ICAM-1 Intercellular adhesion molecule 1 
IDH   Isocitrate dehydrogenase  
IGF-1R  Insulin-like growth factor 1 receptor 




MMP  Matrix metalloproteinases 
MPZL2 Myelin protein zero like 2 
MRE  miRNA response element 
MRI  Magnetic resonance imaging 
MSI2  Musashi RNA binding protein 2 
mTOR  Mammalian target of rapamycin 
NAD(P) Nicotinamide adenine dinucleotide phosphate 
Nt  Nucleotides 
ORF   Open reading frame 
PABP  Poly(A)-binding protein 
PCR  Polymerase chain reaction 
PD1  Programmed cell death protein 1 
PDGFR Platelet-derived growth factor receptor 
PD-L1  Programmed death-ligand 1 
PI3K  Phosphoinositide 3-kinase 
PTH  Parathyroid hormone 
PTHRP Parathyroid hormone-related protein 
RBP  RNA-binding protein 
RFP   Red fluorescent protein 
RISC  RNA-induced silencing complex 
RNA Pol  RNA polymerase 
ROC   Receiver operating characteristic 
RTKs  Receptor tyrosine kinases 
SCID  Severe combined immunodeficiency 
SEM  Standard error of the mean 
shRNA Short hairpin RNA 
SMO  Receptor Smoothen 
SOX9  Sex-determining region Y-Box 9 protein 
SRGAP2  SLIT-ROBO Rho GTPase activating protein 2 
TCI  Tumor cell injection 
TET2  Tet methylcytosine dioxygenase 2 
TF  Transcription factor 
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TGFB  The transforming growth factor beta 
UBE2E3 Ubiquitin conjugating enzyme E2 E3 
UTR  untranslated region 
VEGF  Vascular endothelial growth factor 
VEGF  Vascular endothelial growth factor 





























 Epidemiology and clinical characteristics 3.1.1
Chondrosarcoma is a malignant cartilage-forming tumor which accounts for roughly 20% 
of all bone tumors, making it the second-most frequent primary sarcoma of the bone, above 
Ewing’s sarcoma and below osteosarcoma (Christopher D.M. Fletcher 2002). Its estimated 
overall incidence is 1 patient per 200,000 people per year. Compared to osteosarcoma and 
Ewing’s sarcoma,  which are malignancies with the highest incidences in young patients,  
chondrosarcoma is predominantly a malignancy of adulthood with a wide peak of incidence 
between 30 and 70 years old (Figure 1.A) (Dorfman and Czerniak 1995; Damron, Ward et 
al. 2007). Males are slightly more frequently affected than females without racial or ethnical 
preferences  (Giuffrida, Burgueno et al. 2009; Nie, Lu et al. 2018). 
Chondrosarcoma is commonly located in the bones of the pelvis, followed by the femur, 
proximal humerus and ribs (Figure 1.B) and, as for most of bone tumors, long-lasting local 
pain and swelling  are the most common symptoms (Christopher D.M. Fletcher 2002). Bone 
fractures can also occur in approximately 10% of patients (Björnsson, McLeod et al. 1998). 
Characteristic bone lesions detected by radiography are very important for the diagnosis 
of chondrosarcoma. In long bones, tumors are frequently located in the metaphyseal region 
and they display cortical thickening of the bone, focal mineralization and sometimes bone 
erosion (Figure 1.C) (Soldatos, McCarthy et al. 2011). 
Chondrosarcoma can be classified into three different grades (1, 2 and 3) based on 
histological parameters of tumors, such as cellularity, nuclear size and nuclear staining. 
Grade 2 and grade 3 chondrosarcomas frequently metastasize (10-50% and 53-70%, 










































1977; Fiorenza, Abudu et al. 2002). Patients that experience local recurrence after tumor 
excision most of the time develop metastasis.  Metastatic lesions commonly occur in the 
lungs (Ozaki, Hillmann et al. 1996). Importantly, as chondrosarcoma tumors are virtually 
non-responsive to chemotherapy and radiotherapy, clinical management is limited only to 




























Figure 1: A) Percent distribution of chondrosarcoma patients per age. Adapted from (Damron, Ward et al. 2007). 
B) Frequency distribution of chondrosarcoma tumors across the skeleton. Figure adapted from (van Oosterwijk, 
Anninga et al. 2013). C) X-ray radiography showing a chondrosarcoma tumor presenting lytic lesion in the right 
femur with cortical endosteal scalloping (erosion of the inner cortex, white arrows), chondroid matrix production 
(blue arrow) and cortical thickening (red arrows). Adapted from (Littrell, Wenger et al. 2004)  
 
 Chondrogenic tumors 3.1.2
In order to understand how chondrosarcoma arises (or better said: how it possibly arises, as 
it will be discussed in section 3.1.3 “Etiology”) it is first necessary to remark that 
chondrosarcomas can originate from certain preexisting benign tumors. In addition, 
chondrosarcomas can also give origin to other malignant tumors of the human cartilage. Thus, 
because of the interconnection and the radio-histological similarities between them, they are 
frequently addressed as a broad group of tumors. Ergo, this part of the thesis aims to 
summarize and give a clarified picture of the different chondroid-matrix producing neoplasms, 
that together with chondrosarcoma, are commonly referred as cartilaginous or chondrogenic 
tumors (Fletcher, Unni et al. 2002). Importantly, all chondrogenic variants, benign and 
malignant, are recognized by the World Health Organization (WHO) (Table 1). 
One commonality among all the members of this broad group is that they are all believed to 
develop at the growth plate of bones. Primary chondrosarcoma is the most common 
cartilaginous neoplasm and the most studied one. Depending on the location of the tumors, 
two chondrosarcoma types can be recognized: central (also known as conventional 
chondrosarcoma) and peripheral. The first ones occur at the medullary cavity of bones, 
whereas the latter ones originate in the surface of bones, and although histologically 
indistinguishable, they have genetic differences (Bovée, van Royen et al. 2000).  
Evidence supports that the majority of chondrosarcomas emerge from preexisting benign 
tumor entities, specifically from enchondromas and osteochondromas, given their similar 
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histological appearance and tumor localization. Enchondromas develop in the bone cavity and, 
therefore, are thought to progress towards central chondrosarcoma. Similarly, for being 
superficial bone tumors, osteochondromas can evolve into peripheral chondrosarcoma. Both 
benign tumor types have high survival rates and, typically, complete tumor removal is 
curative. Other benign tumors are recognized (chondroblastoma, periosteal chondroma and 
chondromixoid fibroma), but due to their unknown/unclear link to chondrosarcoma, they will 
not be discussed in the present thesis. 
Several malignant chondrogenic variants also exist and, although they show some 
commonalities with central chondrosarcoma, they are still poorly characterized tumor types. 
The first one is dedifferentiated chondrosarcoma, which accounts for 10% of all 
chondrosarcoma types and it is characterized by a mixture of two defined neoplastic 
components: a cartilaginous tumor juxtaposed with a non chondrogenic sarcoma, which can be 
osteosarcoma, fibroma, rhabdomyosarcoma or others. Importantly, dedifferentiated 
chondrosarcoma may arise from preexisting conventional chondrosarcoma tumors (Bovee, 
Hogendoorn et al. 2010). As it will be addressed in more detail in section 3.1.4.1 (Metastasis 
in chondrosarcoma), the dedifferentiated is the most aggressive chondrosarcoma variant with 
a 5-year overall survival rate lower than 10%. A second rare chondrosarcoma subtype is a 
highly malignant and recurrent tumor named mesenchymal chondrosarcoma (3–10% of all 
chondrosarcomas) which is histologically seen as a mixture of normal cartilage cells together 
with small undifferentiated cells. Lastly, clear cell chondrosarcoma is a low grade variant 
comprising for 2% of all chondrosarcoma that is occurring in the epiphyseal region of long 
bones and it is histologically defined by the presence of clear cells mixed with cartilage 




Tumor type Frequency 




Periosteal chondroma 10% 
Chondromyxoid fibroma 7% 
Malignant   
Conventional central chondrosarcoma 75% 
Secondary peripheral chondrosarcoma 10% 
Dedifferentiated chondrosarcoma 10% 
Clear cell chondrosarcoma 2% 
Mesenchymal chondrosarcoma 2% 
Periosteal chondrosarcoma 1% 
 
Table 1: Chondrogenic tumor types according to the WHO. Figure adapted from (Bovee, Hogendoorn et al. 
2010) 
3.1.2.1 Grading of chondrosarcoma tumors and its challenges 
Conventional chondrosarcoma tumors can progress from poorly aggressive non-metastatic 
variants (Grade 1) to malignant ones (Grade 2 and 3). The assessment of the grading of 
chondrosarcoma is based on different histological and imaging features such as cellularity, 
nuclear atypia, vascularization and aberrant production of extracellular matrix components 
(EMC) within the tumor, with all these factors markedly increasing with tumor grade as 
shown in Figure 2 (Christopher D.M. Fletcher 2002). Collagens (2, 2a and 11), hyaluronan, 
aggrecan and heparin sulfate are possibly the best described ECM components in 
chondrosarcoma (Aigner, Dertinger et al. 1997; Schrage, Hameetman et al. 2009; Totoki, 
Yoshida et al. 2014; Hamada, Nishida et al. 2018). 
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Due to its complexity and lack of reliable biomarkers, grade assessment is known to be an 
arduous task for pathologists, leading with frequency to the erroneous categorizations of 
tumors, especially between Grade 1 and Grade 2 chondrosarcoma cases (Eefting, Schrage et 
al. 2009). The improvement of this low reliability is of outmost relevance for the field, as 
tumor grading is a strong prognostic factor. Additionally, because Grade 1 chondrosarcomas 
are treated differently than Grade 2 and 3 (as described in detail in Section 3.1.5, 
Chondrosarcoma treatment), wrong grading assessment has a direct negative impact on 
clinical management too. Moreover, benign chondrogenic tumors, especially enchondromas, 
can be extremely hard to differentiate from Grade 1 and sometimes even from Grade 2/3 
chondrosarcomas (SLICED 2007), a fact that may explain the marked variation between 
chondrosarcoma outcomes at different clinical centers. Taken all these facts together, the 
discovery of sensitive biomarkers that are specific for tumor subtypes, or the development of 
better imaging methodologies to discriminate them, are both indispensable to improve the 








Figure 2: Changes seen in the cellularity and extracellular matrix distribution during the malignant progression 






Despite the numerous efforts in chondrosarcoma research, its cell origin still remains 
unknown. Nevertheless, a large amount of data supports that chondrosarcomas originate from 
benign chondrogenic neoplasms, being enchondromas and osteochondromas, which are 
thought to develop from the growth plate of bones. The growth plate is the region between the 
epiphysis and the metaphysis of long bones (Figure 3.A). The cartilage cells within the growth 
plate, named chondrocytes, experience a coordinated process of cell differentiation which ends 
up in the formation of hypertrophic chondrocytes. These enlarged hypertrophic cells are 
genetically programmed to secrete different components to the extracellular matrix space 
which are needed for new bone formation. In addition to this, hypertrophic chondrocytes 
engage blood vessels and osteoblasts resulting in newly synthesized bone. It is through this 
process of chondrocyte enlargement and osteoblast attraction that longitudinal growth of bone 
occurs, which is commonly referred to as endochondral bone formation. 
From an anatomical point of view, the strongest evidence supporting that enchondromas 
and osteochondromas arise from chondrocytes of the growth plate are tumor location and 
stage of life of appearance. Both tumors are known to arise at the metaphyseal portion of the 
bone. As newly generated bone originates in that same region, it is likely that these benign 
tumors are product of an erroneous endochondral bone formation process. The second 
important aspect is that enchondromas and osteochondromas usually develop before adulthood 
(even if the detection is done during the adulthood, possibly because they are not painful), 
meaning, at the time when bones are still enlarging in the body and chondrocytes can still 
actively divide. 
From a genetic perspective, an increasing amount of evidence reinforces the hypothesis 
which suggests that the growth plate is the site of origin of these benign entities, that 
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subsequently progress towards chondrosarcoma. Briefly, there are two main signaling 
pathways responsible for bone development during endochondral ossification: the Indian 
Hedgehog (IHH) and the Parathyroid hormone and Parathyroid hormone-related peptide 
(PTH/PTHrP) pathways. The IHH pathway is responsible for chondrocyte differentiation and 
said in other words, it drives the conversion of normal chondrocytes towards pre- and 
hypertrophic chondrocytes (Kobayashi, Chung et al. 2002). The PTHrP pathway, on the other 
hand, guarantees chondrocyte proliferation in the growth plate. Both pathways act in a 
negative feedback loop and this link suggests that their interactions regulate the right pool of 
proliferative and hypertrophic chondrocytes (Figure 3.B) (Kronenberg 2003). Importantly, 
members of both pathways have been reported to be constitutively active in benign 
chondrogenic tumors (Tiet, Hopyan et al. 2006). In addition to this, the deregulation of the 
signaling members of both pathways is more pronounced in high-grade chondrosarcomas, 
suggesting that IHH and PTH/PTHrP are not only required for chondrosarcomagenesis, but 
also for cancer progression (Bovee, van den Broek et al. 2000).  
Given the importance of the IHH/PTHrP signaling axis, many targeted-therapies have been 
tested against protein members of these pathways, as it will be addressed in more detail in 






















Figure 3: A) Schematic representation of the different regions at the terminal bone anatomy. Adapted from 
(Little, Klionsky et al. 2014). B) The IHH and PTHrP signaling pathways are major players in regulating 
differentiation and proliferation of chondrocytes of the growth plate. The PTHrP pathway delays chondrocyte 
differentiation by downregulating IHH activation (1). IHH signaling (through Gli transcription factors) drives 
chondrocyte differentiation causing the longitudinal growth of the bones (2). Additionally, IHH signaling directly 
upregulates PTHrP expression at the end of bones (3) by an unclear mechanism. IHH also stimulates the 
recruitment of perivascular cells and osteoblast and osteoclasts in order to produce new bone. In the case of 
benign chondrogenic tumors and chondrosarcoma, there is deregulation of this feedback loop, resulting in 
constitutive activation of IHH signaling. Figure adapted from (Kronenberg 2003) 
 
 Metastasis 3.1.4
Metastasis is the main cause of mortality in chondrosarcoma patients, and in all cancer 
types as a general rule (Mehlen and Puisieux 2006). Although far from being fully understood, 
the formation of metastasis relies on a chain of multiple coordinated events that result in the 
dissemination of cancer cells into distant tissues, a process commonly known as “the invasion-
metastatic cascade” (Valastyan and Weinberg 2011). The very first step in this cascade 
consists on the initial invasion of the tumor cells into neighboring normal or neoplastic tissues. 
This step is followed by the migration of the cancer cells across the surrounding blood or 
lymphatic vasculature (intravasation). Once in the lumen of vessels, the circulating tumor cells 
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(CTCs) spread throughout the body as part of the normal circulating transit. To increase their 
survival chances CTCs are known to bind to normal circulating cells (platelets and neutrophils 
mainly) (Leblanc and Peyruchaud 2016; Szczerba, Castro-Giner et al. 2019). Importantly, 
those very few cells that manage to survive the immune attack as well as to the oxidative and 
mechanical stress can eventually exit the vasculature barrier and colonize distant organs 
(extravasation). Lastly, tumor cells that reach the parenchyma can divide and form small 
colonies (micrometastases) which after several subsequent cell division rounds can give 
formation to macroscopic metastases (macrometastases). 
In cancer of epithelial origin (carcinomas), a central mechanism in the metastatic process is 
the epithelial-mesenchymal transition (EMT). When going through EMT, epithelial cancer 
cells undergo a genetic reprogramming process that results in the loss of some of its epithelial 
features and the subsequent gain of some mesenchymal-like phenotypic properties. These 
changes confer to cancer cells multiple advantageous features such as an increased invasive 
potential, resistance to chemo- and radiotherapeutic agents or an enhanced ability to degrade 
extracellular matrix components (EMC) (Hanahan and Weinberg 2011). From a genetic 
regulatory standpoint, EMT requires the coordination of multiple transcription factors (TFs) 
for the activation of numerous regulatory gene networks that results in the molecular 
reprogramming of the cancer cells.  
In contrast, in cancer types of mesenchymal origin like chondrosarcoma, the role of EMT-
related processes is very unclear. In fact, linking EMT with sarcoma might sound paradoxical, 
as primary tumors are mesenchymal ab initio. Still, some evidence suggests that specific 
sarcoma subtypes might experience EMT-like processes. For example, the inverse process to 
EMT, named mesenchymal-to-epithelial transition (MET), has been noted in sarcomas. This is 
characterized by an (incomplete) epithelial differentiation of the tumor cells, resulting in 
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lowered tumor malignancies. This is supported by the fact that expression of conventional 
EMT TFs, such as Snail, Slug and Twist has been reported in sarcomas. This suggests the 
possibility that certain sarcomas may experience a mixed state characterized by the presence 
of both, epithelial and mesenchymal features (Kahlert, Joseph et al. 2017; Sannino, Marchetto 
et al. 2017) Although an increasing amount of evidence supports that some sarcoma types may 
go through EMT-like processes that contribute to cancer malignancy, the field is still far from 
being fully understood and additional studies are required to unravel the mechanisms 
governing these phenomena.  
3.1.4.1 Metastasis in chondrosarcoma 
Metastasis is the main cause of mortality in patients with chondrosarcoma and 23% of all 
patients develop metastasis at some point during their disease. However, if one does not take 
into account all chondrosarcoma Grade 1 cases – which are commonly acknowledged as non-
metastatic- the remaining combined chondrosarcoma Grade 2 and 3 metastasize on average in 
50% of all patients (Evans, Ayala et al. 1977; Fiorenza, Abudu et al. 2002). Due to the direct 
link of grading with high risk of developing metastasis, it is key predictor of clinical behavior 
in chondrosarcoma. The five-year survival for chondrosarcoma Grade 1 patients is around 
90%, while for chondrosarcoma Grade 2 and Grade 3 is 60% and 40% respectively (Figure 
4.A) (Fiorenza, Abudu et al. 2002; Andreou, Ruppin et al. 2011). Metastases occur with a 
strong preference in the lungs, accounting on average approximately 80% of all metastatic 
cases. Other less common sites include skin, soft tissue, brain, spine and liver (Evans, Ayala et 
al. 1977; Ozaki, Hillmann et al. 1996).  
Approximately 10% of all chondrosarcoma patients develop tumors that cannot be treated 
surgically, usually referred to as unresectable or non-resectable conventional chondrosarcoma. 
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The most common causes of unresectability are tumor location, tumor size and enhanced 
metastatic spread at time of diagnosis. Most unresectable tumors originate at the skull and the 
pelvis, making wide-margin surgeries at these sites very challenging (Bloch, Jian et al. 2010). 
These patients face worse survival rates than patients with resectable tumors (Figure 4.B) (van 
Maldegem, Gelderblom et al. 2014). 
Not surprisingly, benign chondrogenic tumors (enchondromas and osteochondromas) do 
not metastasize. Nevertheless, as they can progress towards conventional chondrosarcoma, 
they may result in metastasis development if not treated on time. On the contrary, 
dedifferentiated chondrosarcomas are highly metastatic resulting in 5-year survival rates 
between 7% and 18%, making it the most lethal chondrosarcoma variant(Christopher D.M. 
Fletcher 2002).   
Little is known about the molecular mechanisms behind chondrosarcoma metastasis in the 
lungs. It has been reported that upon methylation of CpG islands, chondrosarcoma cells 
experience an EMT-like process, characterized by the changes in the expression of different 
epithelial markers (Fitzgerald, Gourronc et al. 2011).  A positive correlation between Twist1 
levels and tumor grade was also reported in chondrosarcoma (Wu, Huang et al. 2016). Several 
other studies have identified various gene candidates that can be linked to the metastatic 
process in chondrosarcoma, but the amount of functional evidence is still insufficient. For 
example, the expression of several Matrix metalloproteinases (MMPs) was associated with the 
metastatic potential of chondrosarcoma tumors (Hou, Hsiao et al. 2009; Malcherczyk, Heyse 
et al. 2018).  Additionally, upregulation of the intercellular adhesion molecule‐1 (ICAM‐1) – a 
gene linked with metastasis in some carcinomas- was found to increase the migratory capacity 
of chondrosarcoma cells (Fong, Lin et al. 2012). Similarly, other factors whose involvement in 
the metastatic process has been better described for other tumor types (integrins and the gene 
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COX2) were reported to contribute to the metastatic phenotype of chondrosarcoma cells in 
vitro (Tang 2012). 
 











Figure 4: A) Cumulative survival rates according to chondrosarcoma grading. Figure adapted from (Fiorenza, 
Abudu et al. 2002). B) Overall survival for patients with unresectable chondrosarcoma tumors of mixed grades 
(1,2 and 3). Figure adapted from (van Maldegem, Gelderblom et al. 2014) 
 
 Chondrosarcoma treatment 3.1.5
3.1.5.1 Surgery 
For all grades and subtypes of nonmetastatic chondrosarcoma, complete surgical tumor 
removal stands for the only therapeutic option (Figure 5). The chosen treatment generally is a 
wide, en-bloc, excision for all central malignant (Grade 2/3 and dedifferentiated) and 
peripheral chondrosarcoma tumors. For central low Grade 1 chondrosarcoma tumors, 
curettage is the usual treatment, combined with adjuvant therapy (for example, phenolization 
or cryosurgery with liquid nitrogen), then followed by filling the cavity with bone graft 

















Figure 5: Flowchart of the surgical management of central and peripheral chondrosarcoma. Figure adapted from 
(Gelderblom, Hogendoorn et al. 2008) 
 
3.1.5.2 Radiotherapy 
Chondrosarcoma cells are slow-diving making them a complicated target for 
radiotherapeutic treatments partly explaining why chondrosarcoma tumors are highly resistant 
to these treatment modalities (Onishi, Hincker et al. 2011). Nevertheless, radiotherapy can be 
used in two different scenarios and usually for palliative treatment: when the tumor resection 
was incomplete during surgery and for unresectable cases (Gelderblom, Hogendoorn et al. 
2008; Riedel, Larrier et al. 2009). Given the limited efficacy of previously tested 
radiotherapeutic regimens, there are currently various ongoing clinical trials testing novel 





Systemic drug treatments have existed for many decades in single-drug or combined 
regimens and for certain cancer types they are extremely effective therapies. Similarly to 
radiotherapy, chondrosarcoma tumors are highly resistant to conventional chemotherapies 
(doxorubicin, cisplatin, gemcitabine, and others), reflected in poor outcomes when surgery is 
not curative in patients (Italiano, Mir et al. 2013).  The cartilage architecture -poorly 
vascularized and with a high abundance of extracellular matrix components- very likely plays 
a role in chemoresistance as it is not a permeable tissue for drug delivery. Additionally, 
chondrosarcoma tumors are highly heterogeneous, and there is still a big debate about which 
cell types should mainly be targeted by drug treatments (David, Blanchard et al. 2011). 
Nevertheless, most likely the cartilage niche is not the unique contributor to 
chemoresistance since chondrosarcoma cells in vitro can tolerate high doses of different 
chemotherapeutic drugs. In this regard, numerous works have tried to elucidate the possible 
molecular mechanisms behind this process. For example, it is well reported that the protein P-
glycoprotein is highly expressed in chondrosarcoma. This protein is an ATP-dependent 
membrane pump which secretes drugs and other small molecules to the extracellular space. 
Importantly, 90% of all cartilaginous tumors are positive for P-glycoprotein immunostaining 
which makes them insensitive to cyclophosphamide, doxorubicin, vincristine, cisplatin, 
methotrexate and dacarbazine (Terek, Schwartz et al. 1998; Wyman, Hornstein et al. 1999). 
Moreover, there is evidence that chondrosarcoma overexpress several anti-apoptotic genes 
such as BCL-2 and survivin (also known as BIRC5), preventing cell death induced by 
conventional chemotherapy (Kim, Kim et al. 2009; Lechler, Renkawitz et al. 2011). 
There are other possible mechanisms of drug resistance utilized by chondrosarcoma cells, 
such as expressing large amounts of telomerase, hypoxia inducible factor-1α (HIF-1α) or 
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cyclooxygenase-2 (COX-2) which could confer cellular immortality, generate new vasculature 
and promote inflammation, respectively (Onishi, Hincker et al. 2011). 
 
3.1.5.4 Targeted therapies 
Given the lack of efficacy of available treatments, there is an urgent need for the 
development of novel therapeutic approaches. Current research efforts are focused on 
targeting molecular factors that have been shown to be active or to contribute to 
chondrosarcoma pathogenesis and are listed below. Additionally, a brief summary of the 
clinical studies supporting the development of novel treatments in chondrosarcoma is 
presented in Table 2. 
 
1) Isocitrate dehydrogenase 
Recent studies have shown that isocitrate dehydrogenase 1/2 (IDH1/2) heterozygous 
mutations occur in various cancers, including chondrosarcoma (Amary, Bacsi et al. 2011).  
IDH1 or IDH2 are enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (αKG), 
in a NAD(P)-dependent fashion, as part of the Krebs cycle. Mutated IDH1 and IDH2 enzymes 
produce d-2-hydroxyglutarate (2HG) from αKG conversion. It has been reported that for 
conventional chondrosarcoma approximately 50% of all tumors harbor IDH1/IDH2 mutations. 
In addition to this, in benign enchondromas IDH1/IDH2 mutations are present in 87% of 
cases, while for dedifferentiated chondrosarcoma in 54% of all cases. Interestingly, neither 
benign (osteochondromas) nor malignant (peripheral chondrosarcoma) superficial 
cartilaginous carry IDH1/IDH2 mutations (Schaap, French et al. 2013).  
The accumulation of the 2HG metabolite generates various cellular changes, mostly 
through epigenetic regulation by causing hypermethylation of certain DNA regions by TET2 
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dioxygenase activation, which could potentially lead to carcinogenesis (Molenaar, 
Maciejewski et al. 2018). In vitro studies showed that treatment of cells with a IDH inhibitors 
drastically decreases the aberrant production of 2HG in chondrosarcoma cell lines, although is 
not yet clear if IDH inhibition affects cell proliferation and survival (Polychronidou, 
Karavasilis et al. 2017). Importantly, IDH1/2 mutations have been recently shown to be 
negative prognostic factors in chondrosarcoma patients (Lugowska, Teterycz et al. 2018). 
 
2) The hedgehog pathway 
As mentioned previously in section 3.1.3 (Etiology), the IHH and PTHrP signaling 
pathways are key players in the regulation of chondrocyte proliferation and differentiation. 
Therefore, it is not surprising that changes on the expression levels and/or mutations in any of 
the components of these pathways may be detrimental for bone development and eventually 
contribute to chondrosarcoma pathogenesis. In addition to this, high-grade chondrosarcoma 
tumors are known to express high levels of IHH factors (Tiet, Hopyan et al. 2006). By 
inhibiting the IHH pathways in chondrosarcoma, cells are less proliferative and migratory 
(Xiang, Jiang et al. 2014), and it was also shown in vivo that this IHH blockade causes tumor 
growth inhibition (Campbell, Nadesan et al. 2014). 
Given the promising results observed in pre-clinical settings with IHH drug inhibitors, they 
were subsequently tested in two independent chondrosarcoma clinical studies. Unfortunately, 
none of them showed a clinical benefit (BusinessWire 2012; Italiano, Le Cesne et al. 2013). 
One possible explanation for the failure of both trials could be that both drugs tested (saridegib 
and vismodegib) are inhibitors of the IHH receptor smoothen (SMO), which might be 




3) Receptor tyrosine kinases: 
3.1) The PI3K–Akt–mTOR pathway  
The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is constitutively activated in 
multiple cancer types, causing reduced apoptosis and enhanced cell proliferation. The pathway 
is activated by ligands that bind to  receptor tyrosine kinases (RTKs), such as IGF-1R and 
PDGFR, that have been shown to be active in chondrosarcoma (Schrage, Briaire-de Bruijn et 
al. 2009; Zhang, van Oosterwijk et al. 2013). These studies demonstrate that RTK activation in 
chondrosarcoma is directly linked to the PI3K–Akt–mTOR signaling as RTK inhibitors 
diminish phosphorylation of downstream effectors (Akt and S6 kinase) resulting in 
chondrosarcoma cell growth inhibition in vitro and in vivo.  
Additionally, mTOR pathway was shown to be important in chondrosarcoma and its 
blockade decreased the in vitro proliferation rate of cells and prevented tumor recurrence in a 
chondrosarcoma rat model (Perez, Decouvelaere et al. 2012). Combining mTOR inhibitors 
with chemotherapeutic agents has also been tested in chondrosarcoma. For example, 
chondrosarcoma patients with unresectable tumors who were treated with mTOR inhibitors 
plus cyclophosphamide showed promising disease control rates, which stimulated the 
development of an ongoing phase II trial of sirolimus with cyclophosphamide to study safety 
and efficacy (EudraCT: 2013-005155-32). A very recent phase II study testing the combined 
effect of doxorubicin (in a liposomal formulation) together with the mTOR inhibitor 
temsirolimus proved in roughly half of the enrolled patients a progression free survival of 315 
days (Trucco, Meyer et al. 2018). 
The activation of the PI3K–Akt pathway caused by IGF-1R is a known mechanism of 
mTOR-inhibitor resistance in cancer. Reduced AKT activation levels caused by combined 
regimens of IGF-1R and mTOR inhibitors in different studies stimulated the design of 
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multiple clinical trials to test such combinations in sarcoma patients with some promising 
results (Polychronidou, Karavasilis et al. 2017).  Lastly, inhibition of PDGFR with imatininb 
has not shown encouraging results for the treatment of a cohort of patients with unresectable 
chondrosarcoma tumors (Grignani, Palmerini et al. 2011). 
 
3.2) VEGF and angiogenesis 
Tumor vascularization is a fundamental step in cancer development and in chondrosarcoma 
it has been shown to contribute to pathogenesis and tumor progression (Kubo, Shimose et al. 
2013; Liu, Chen et al. 2014) and its inhibition demonstrated to potently inhibit tumor growth 
in a xenograft mouse model (Klenke, Abdollahi et al. 2007). 
In addition to these results, when the angiogenesis mediator COX-2 (expressed in 2/3 of all 
chondrosarcoma tumors) is inhibited with the drug celecoxib, chondrosarcoma cell viability is 
affected in vitro and tumor growth is inhibited in chondrosarcoma xenografts (Schrage, 
Machado et al. 2010).  
Currently there is an ongoing Phase II study (NCT01330966) assessing the clinical efficacy 
and safety of a broad RTK inhibitor, pazopanib, which has VEGF, cKIT and PDGFR among 
some of its targets. All enrolled patients have surgically unresectable chondrosarcoma tumors. 
A similar approach follows the ongoing Phase I/II trial (NCT02389244) by testing the multi-
RTK inhibitor regorafenib in a cohort of patients with bone metastatic sarcomas.  
4) Histone deacetylases 
Epigenetic factors are strong modulators of gene expression in cells and regulate numerous 
cellular processes. It has been widely reported that their deregulation can contribute to the 
malignant cellular transformation of cells. Histone acetylates and deacetylases are epigenetic 
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factors responsible for activating or deactivating gene expression in certain genomic regions 
by changing the RNA polymerases accessibility to the chromatin (Sharma, Kelly et al. 2010). 
In chondrocytes, numerous studies have shown that the regulation of histone 
acetylation/deacetylation is a very active process, underlying its relevance for normal cartilage 
homeostasis (Guo, Zhao et al. 2014; Li, Wei et al. 2014). Most importantly, direct inhibition 
of histone deacetylases (HDACs) inhibited the growth of chondrosarcoma cells by inducing 
cell cycle arrest and apoptosis and diminishing tumor growth in vivo, demonstrating that 
HDAC inhibitors can be promising drug therapies (Sakimura, Tanaka et al. 2007; Zhu, Gu et 
al. 2015). Currently, there is a Phase II clinical study testing the clinical efficacy of the HDAC 




It has recently been described that chondrosarcoma tumors are infiltrated by various types 
of immune cells (such as CD8+, CD3+, CD4+ and CD163+), suggesting that the immune 
system could play an important role in chondrosarcoma pathogenesis. For example, CD163+ 
macrophage depletion slowed down tumor progression in a Swarm chondrosarcoma rat model 
(Simard, Richert et al. 2016).  In addition to this findings, a 2016 study demonstrated that PD-
L1 and HLA class I expression accompanied with T-cell and macrophage tumor infiltration 
occurs in 50% of all dedifferentiated chondrosarcomas patients (Kostine, Cleven et al. 2016). 
Given these results, there are currently two Phase II clinical studies assessing the clinical 
benefit of immune checkpoint inhibitors in chondrosarcoma. So far it has been reported that 
one of them, pembrolizumab, exhibited partial tumor remission in one out of the six patients 
enrolled with dedifferentiated chondrosarcoma (NCT02301039). 
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6) Other targeted therapies 
The enzyme EZH2 is a protein that participates in the transcriptional repression through 
histone methylation of certain genes. In different cancer types, EZH2 has been found to be 
deregulated or mutated and to contribute to pathogenesis (Kim and Roberts 2016). In high 
grade chondrosarcoma cell lines, EZH2 was found to be highly expressed, and its depletion by 
the DZNep inhibitor caused cell death in vitro (Girard, Bazille et al. 2014). Similarly, in 
myxoid chondrosarcoma the EZH2 depletion also resulted in cell proliferation inhibition 
(Shen, Cote et al. 2016).  There are currently two ongoing clinical trials testing the clinical 
efficacy of an EZH2 inhibitor (tazmetostat) in pediatric (NCT02601937) and adult 
(NCT02601950) patients with myxoid chondrosarcoma, a tumor type with no clear evidence 
of cartilaginous differentiation. 
On the other hand, zoledronic Acid is also currently tested in a Phase 1B clinical trial study 
as neoadjuvant therapy (NCT03173976). In few words, zoledronic acid slows down bone 
resorption and produces beneficial effects on bone metabolism in cancer patients. In 
chondrosarcoma, it was already shown that zoledronic acid may have a positive impact in 
tumor-associated pain and also in improving patient quality of life, independently from other 















Study Population Status 
Targeting IDH mutations 
AG-221 NCT02273739 Oral IDH2  
inhibitor 
Phase I/II Study of orally administered 
 AG-221 in subjects with 
advanced solid tumors, including 





AG-881 NCT02481154 Oral IDH1/2 
inhibitor 
Phase I  Advanced solid tumors, 





AG-120  NCT02073994 Oral IDH1  
inhibitor 
Phase I  Study of orally administered AG-
120  in subjects with advanced 







NCT02496741 Oral antidiabetic 
(metformin) 
 and oral 
antimalarial 
Phase 1B IDH1/2-mutated Patients With 





PI3-Akt-mTOR pathway and RTKs 
Everolimus NCT02008019 mTOR  
inhibitor 
Phase II A phase II study of everolimus in 




to everolimus  
unavailability 
Imatinib NCT00928525 PDGFR Phase II Study to determine if imatinib  is 
active in diseases - such as 
chondrosarcoma - expressing 






NCT02821507 mTOR inhibitor 
(sirolimus) 
+  DNA crosslinker 
(cyclophospamide) 
Phase II  Sirolimus and cyclophosphamide 
in metastatic or unresectable 




Dasatinib NCT00464620 multi-RTKs  
inhibitor 





Regorafenib NCT02389244 VEGFR and other 
RTKs 
Phase II A study evaluating efficacy and  
safety of regorafenib in patients 




Pazopanib NCT01330966 VEGFR and other 
RTKs 
Phase II Study of pazopanib in the 
treatment of surgically 





NCT01532687 Nucleoside analog 
(gemcitabine)  +  
VEGFR and other 
RTKs  (pazopanib) 
Phase II Gemcitabine hydrochloride with 
or  without pazopanib 
hydrochloride in treating 







Pazopanib NCT02066285 VEGFR and other 
RTKs 
Phase II Trial of pazopanib in patients 





Romidepsin NCT00112463 HDAC inhibitor Phase II Patients with metastatic or 




Immune Checkpoint Inhibitors 
Pembrolizumab NCT02301039 Anti-PD1 Phase II This is a multi-institutional phase 
II study of pembrolizumab in 
patients with advanced 
sarcomas. This study will have 
two treatment groups, one 
group for patients with soft 
tissue sarcoma and one group 










Phase 1B This study investigates the 
safety/toxicity and  
potential anti-tumor activity of 
sequential administration of 
nivolumab and escalating doses 










Phase II A phase II of nivolumab plus 
ipilimumab in 





Tazemetostat NCT02601950 EZH2 inhibitor Phase II A phase 2 study of the EZH2 
inhibitor tazemetostat in adult 
subjects with relapsed or 
refractory INI1-negative tumors 
or synovial sarcoma 
Ongoing, 
recruiting 
Tazemetostat NCT02601937 EZH2 inhibitor Phase I A Phase 1 study of the EZH2 
inhibitor tazemetostat in 
pediatric subjects with relapsed 
or refractory INI1-negative 
tumors or Synovial Sarcoma 
Ongoing, 
recruiting 
Zoledronic Acid NCT03173976 Anti-Osteoclast 
Therapy 
Phase 1B  Clinical trial assessing the safety 
and efficacy of neoadjuvant 
zoledronic acid in patients with 





Table 2: Ongoing and recently finished clinical trials in various chondrosarcoma subtypes. Adapted from 





Although the conventional approaches for the development of novel therapeutic options has 
not far succeeded in chondrosarcoma, the field is moving rapidly, which is echoed in the 
growing number of clinical studies. Nevertheless, given this unmet need, new alternatives for 
the discovery of molecular targets must be exploited. In this regard, microRNAs have been 
widely shown as key contributors to cancer development and progression and, additionally, as 
sensitive and specific biomarkers for certain cancer types. Thus, the identification of relevant 
microRNAs in chondrosarcoma may represent a crucial path for the identification of 























3.2 microRNAs  
microRNAs (miRNAs) are small non-coding RNAs of ~20-30nt in length that modulate 
gene expression. These molecules were firstly characterized in 1993 by Ambros and 
colleagues as endogenous regulators of genes in Caenorhabditis elegans  (Lee, Feinbaum et 
al. 1993). Although there are exceptions, the vast majority of miRNAs are transcribed from 
precursor-primary miRNA molecules (pri-miRNA) in defined genomic regions, which then 
are further processed into the mature miRNAs, as it will be discussed in more detail on the 
following section (miRNA biogenesis and regulation) .  
As a general rule, mature miRNAs modulate gene expression by base-pairing with 
complementary specific regions within the 3’UTR sequence of a given gene, causing mRNA 
expression inhibition (Bartel 2004). Nevertheless, it is also known that this interaction can 
occur at the 5’ UTR, although much less frequently (Lee, Ajay et al. 2009). Additionally, it 
has been demonstrated that under certain circumstances a minority of miRNAs can enhance 
gene expression of mRNAs, instead of repressing it. 
miRNAs play a key role in animal development and they are also involved in virtually 
every existing biological process within cells, such as proliferation, differentiation, apoptosis, 
and many others. Because of their strict involvement in cell and tissue homeostasis, 
deregulation of miRNAs levels can contribute to different human diseases, such as cancer 
(Alvarez-Garcia and Miska 2005). Consequently, miRNA-based therapeutic strategies have 
been developed in order to restore the normal levels of deregulated miRNAs (Krutzfeldt, 
Rajewsky et al. 2005; Christopher, Kaur et al. 2016). 
Lastly, miRNAs are found in distinct body fluids as extracellular miRNAs, either 
associated with proteins or within small vesicles, and they are part of a sophisticated 
mechanism of cell-to-cell communication (Sohel 2016). 
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 miRNA biogenesis and regulation 3.2.1
The synthesis of miRNAs is complex multistep process dependent on a RNA polymerase II 
transcription occurring in the cell nucleus (Lee, Kim et al. 2004). Most of miRNAs are located 
within intronic regions of protein-encoding genes whereas a small minority within exons. 
Very commonly, these intragenic miRNAs regulate the expression levels of the gene(s) that 
they are “embedded” in. The remaining miRNAs –those which are not located within genes, 
and are therefore known as intergenic- are transcribed independently, as they have their own 
promoter regions. Although there are multiple alternative ways in which cells synthesize 
miRNAs, the dominant one is the canonical biogenesis pathway. This pathway (described in 
detail in Figure 6) consists of the initial transcription (by RNA polymerase II) of a pri-miRNA 
precursor of 1-3 kb which is immediately processed in the nucleus by the Drosha/ DGCR8 
complex into a ~70 nt pre-miRNA molecule with a double-stranded hairpin loop region in its 
structure. These pre-miRNAs are then transported to the cytoplasm by a nuclear export protein 
named Exportin 5. Once in the cytosol, the Dicer/TRBP complex excises the pre-miRNA into 
~22 bp double-stranded miRNA structures (miRNA/miRNA*) which are afterwards separated 
into two mature miRNAs. One of these strands is degraded based on thermodynamic stability 
of the two ends of the RNA duplex (Schwarz, Hutvagner et al. 2003) and only one mature 
miRNA remains. The latter one is loaded into Argonate (AGO) to form the RNA-induced 
silencing complex (RISC).  
Similarly to protein-encoding genes, miRNA transcription can be regulated by different 
effectors. The expression of miRNA genes in close proximity to CpG islands can be affected 
by methylation (Han, Witmer et al. 2007). Other mechanisms of miRNA expression do exist, 
for example, a small fraction of them are controlled by circadian rhythm regulation (Cheng, 
Papp et al. 2007). Several other processes mediate miRNA abundance at a posttranscriptional 
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level, such as miRNA edition, target transcript abundance (“sponging”) or by changes 
generated by specific factors during miRNA biogenesis (Cai, Yu et al. 2009; Gebert and 























Figure 6: The canonical pathway is the principal 
pathway for miRNA synthesis. Here, pri-miRNAs 
(1-3kb long) are transcribed by RNA Pol II from 
their genes and then excised to pre-miRNAs by 
the DGCR/Drosha complex.  DGCR8 recognizes 
a specific sequence motif within the pri-miRNA 
while Drosha (an RNAse III enzyme) cuts the pri-
miRNA duplex at the start of the hairpin structure 
giving a pre-miRNA as product. The transport of 
pre-miRNAs towards the cytoplasm is mediated 
by the protein Exportin 5 in a GTP-dependent 
fashion.  In the cytoplasm, the enzyme Dicer 
removes the terminal loop of the pre-miRNA 
generating as a product a dsRNA duplex, which 
can be loaded into Argonaut (AGO1-4, in 
humans) in an ATP-dependent way. The 
orientation of each strand gives the name of the 
mature miRNA (either 5p or 3p). One strand will 
remain with AGO (guide strand) whereas the 
other one (passenger strand) will be degraded, a 
process subjected to cell type and environmental 
factors, ranging from equal proportions to one 
strands predominating over the other one. Figure 
adapted from (Gebert and MacRae 2019) 
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 miRNA gene-mediated regulation 3.2.2
As already mentioned, the dominating gene expression mechanism mediated by miRNAs 
involves the direct interaction between certain residues of a mature miRNA with the 3’ UTR 
of a particular mRNA target transcript, resulting in gene expression inhibition (miRNA-
mediated upregulation of a target can also occur, but it is extremely rare). Additionally, 
miRNAs may also bind to 5’-UTR regions of genes, but their frequency of occurrence is very 
low. 
Interestingly, bioinformatic analysis on the conserved miRNA binding sites within mRNAs 
suggests that potentially 30-60% of all human genes are regulated by miRNAs (Lewis, Burge 
et al. ; Friedman, Farh et al. 2009). In this regard, there are three main mechanisms that cells 
use to silence target genes by miRNA direct regulation. One of them is the site-specific 
cleavage via RISC which, as noted in section 3.2.1, involves the protein AGO bound to a 
mature miRNA. The specificity of the RISC complex against an mRNA target depends on the 
degree of complementarity between the miRNA seeding sequence and the UTR, also known 
as the miRNA response element (MRE). If the degree of complementary in a given 
miRNA:MRE is high (full complementarity), what will happen is that the mRNA will be 
cleaved by RISC. On the other hand, if there is not full complementarity between the 
miRNA:MRE (as it happens in the majority of cases in animal cells) AGO will not exert its 
endonuclease activity over the mRNA transcript. Instead, there will be a non-cleavage mRNA 
repression, either by mRNA destabilization or translational repression (Figure 7). The first 
needs the recruitment of deadenylating proteins (also known as PABP, which remove mRNA 
poly-A tails) and decapping proteins towards the RISC complex, resulting in the 
destabilization and degradation of the target mRNA (O'Brien, Hayder et al. 2018). Inhibition 
of translation is a less well understood phenomenon (probably due to the presence of 
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numerous mechanisms) that possibly occurs by RISC preventing the formation of a circular 
complex, which is necessary for the correct assembly of the ribosome to initiate protein 
synthesis. Regardless the mechanisms for miRNA-dependent gene expression inhibition, the 









Figure 7: Representative illustration of the different molecular mechanisms for miRNA-mediated gene 
expression inhibition. ORF = open reading frame. Adapted from (Piva, Spandidos et al. 2013) 
 
 miRNA clusters and families 3.2.3
miRNAs can be transcribed individually or as a part of a long polycistronic transcript 
referred to as miRNA cluster. These are frequently composed of two or three miRNAs 
(although clusters with 6 or more miRNA genes exist) and coordinate complex regulatory 
mRNA networks and fine-tune the regulation of multiple biological processes. Members of the 
same cluster do not necessarily have similarities in their sequences (Aravin, Lagos-Quintana et 
al. 2003), and given their high degree of evolutionary conservation, it is very likely that many 
clusters were generated by de novo duplication of a miRNA. This could have conferred an 
adaptive advantage to the harboring cell, as multiple miRNAs exert a more robust regulation 
than individual miRNAs (Wang, Luo et al. 2016). When miRNAs from a cluster have similar 
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seed sequences -thus they share similar mRNA targets- we call them miRNA families. It is 
worth mentioning that is not exclusive for members of a miRNA family to be produced from a 
same transcript as they can originate from different chromosomes and still be part of the 
family as long as they share a high degree of sequence homology, at least in the seeding region 
(the miR-200 family is a well-studied case) (Tanzer and Stadler 2004). 
Importantly, mutations in miRNAs or aberrant regulation of miRNA production often lead 
to the development of diseases, such as cancer (Ardekani and Naeini 2010). 
 
3.3 miRNAs in cancer 
The deregulation of one or more miRNAs can have severe negative consequences in human 
cells. The involvement of miRNAs in cancer was firstly reported on 2002 (Calin, Dumitru et 
al. 2002) and since then the field has grown exponentially (>35,000 PubMed hits as of March 
2019). Numerous miRNAs are nowadays known to contribute to different stages of cancer 
pathogenesis, such as metastasis, resistance to chemo and radiotherapy, cell proliferation, 
EMT, etc. (Peng and Croce 2016). miRNAs that are over-expressed in cancers may function 
as oncogenes (and therefore are called oncomiRs), whereas downregulated may indicate a 
tumor suppressor function (Lee and Dutta 2009).  
Studying the role of miRNAs in cancer can be challenging. On the one hand, most 
phenotypic traits are regulated by more than just one miRNA, and these may not be related or 
even similarly deregulated. On top of this, tumors are heterogeneous by nature and not all cell 
types within a tumor might suffer from miRNA deregulation in the same way. One must also 
take into account that miRNA function in oncogenesis can also be context dependent 
(subjected to the differentiation status of cells, for example). Secondly, one miRNA can 
regulate numerous gene targets -and one target can be regulated by many miRNAs- so 
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deciphering the main contributors of these complex networks is a key point towards 
understanding the role of a given miRNAs in the disease. 
In tumors,  downregulated miRNAs are more abundant than upregulated ones (Lu, Getz et 
al. 2005). There is a broad array of mechanisms behind miRNA downregulation. One of them 
is the transcriptional silencing caused by hypermethylation at miRNA regulatory regions. 
Interestingly, many miRNA loci associated with CpG islands have been reported to be 
sensitive to methylation status (Weber, Stresemann et al. 2007). Additionally, roughly half of 
human miRNAs are located within fragile genomic regions, suggesting that the 
downregulation can also occur due to genomic loss of those DNA regions (Calin, Sevignani et 
al. 2004). Germline mutations within the miRNA sequence (especially on the seeding region) 
can affect drastically the thermodynamic interactions bridging miRNA:mRNA parings. It is 
also possible that the mutations in the seeding region of a miRNA can affect the regulation of 
new genes that were not targeted in the wild type condition. Moreover, mutations or 
deregulation in genes encoding miRNA-biogenesis machinery (such as Drosha or Dicer) have 
also been shown to be deleterious and to contribute to cancer (Kumar, Lu et al. ; Thomson, 
Newman et al. 2006). Lastly, transcription factors can also bind to miRNA promoter regions 
and reduce their expression (Jansson and Lund 2012). 
On the other hand, upregulation usually occurs due to epigenetic regulation, activation 
mediated by transcription factors or by duplication of miRNA-encoding DNA regions (Peng 
and Croce 2016). 
  
 miRNAs in chondrosarcoma: the unexplored field 3.3.1
When compared to other types of sarcoma, such as osteosarcoma, the biological relevance 
of miRNAs in chondrosarcoma is still far from being well characterized (the Pubmed search 
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“miRNA + chondrosarcoma” gives <60 hits whereas the number is ~1,000 for osteosarcoma, 
as for March 2019). On top of this, most of the published studies included only limited in vitro 
functional data, without addressing in vivo functionality. 
To the present date, there is limited global miRNA data from cancerous chondrogenic 
tissues. Past efforts have positively contributed to a better characterization of miRNA 
signatures in tumors of the cartilage. However, they have some limitations as they either 
included only a small number of chondrosarcoma clinical samples (and all with the same 
grading) (Sui, Liu et al.) or they chose almost-obsolete and less precise discovery approaches 
(Yoshitaka, Kawai et al. 2013). Ergo, these studies have not represented a very prolific source 
of candidate miRNAs that might be relevant for chondrosarcoma progression. Instead, several 
of the studied miRNAs in chondrosarcoma have possibly been chosen for being relevant in 
other cancer types or malignancies of the cartilage (i.e. arthritis). 
Many individual deregulated miRNAs have been linked to chondrosarcoma aggressiveness 
(Li, Wang et al. 2015; Sun, Charbonneau et al. 2015; Bao, Ren et al. 2017),  angiogenesis 
(Liu, Chen et al. 2014; Huang, Chang et al. 2016) and therapy resistance (Zhu, Wang et al. 
2014; Tang, Zheng et al. 2016). Moreover, other studies have pointed out the involvement of 
miRNAs in chondrogenesis and have identified targets that are known to be deregulated in 
chondrogenic tumors, such as the master chondrogenic factor SOX9 and VEGF (Yoshitaka, 
Kawai et al. 2013; Li, Wang et al. 2015; Sun, Charbonneau et al. 2015). Interestingly, none of 
the published studies on miRNAs in chondrosarcoma have taken miRNA clusters or families 




 Circulating miRNAs 3.3.2
A large volume of data indicates that small non coding RNAs (miRNAs) can greatly 
facilitate the right clinical characterization of tumors and their tissue of origin (Rosenfeld, 
Aharonov et al. 2008). In sarcomas, miRNA profiling in tumor tissue was shown to be a 
potent tool for tumor subtype classification, as well as for the assessment of aggressiveness 
and response to therapy (Subramanian, Lui et al. 2008; Renner, Czwan et al. 2012; Boro, 
Bauer et al. 2016; Wiemer, Wozniak et al. 2017).  
Importantly, miRNAs can also be found in different body fluids, such as serum and plasma 
(Chen, Ba et al. 2008). Several studies have demonstrated that in the bloodstream, miRNAs 
are highly stable. When naked miRNAs are exogenously spiked into the bloodstream, they get 
immediately degraded, suggesting that endogenous miRNAs can resist RNAse degradation 
(Mitchell, Parkin et al. 2008). Nowadays, we know that this protection comes from the 
association of miRNA with proteins or for being packed within extracellular vesicles of 
different sizes (Figure 8). Although is not entirely clear how it occurs, circulating miRNAs can 
mediate cell-to-cell communications (Creemers Esther, Tijsen Anke et al. 2012). Importantly, 
thanks to recent technological advances, circulating miRNAs can be rapidly and accurately 
quantified by different affordable methodologies (Schwarzenbach, Nishida et al. 2014). One 
important technical aspect to take into consideration when measuring circulating miRNA 
levels is to normalize their expression against endogenous and exogenous (spike-in) reference 
miRNAs Endogenous “housekeeping” circulating miRNA are disease specific and have to be 
determined empirically (Schwarzenbach, da Silva et al. 2015). 
Taken all these aspects into account, the potential of circulating miRNAs as blood-based 
non-invasive biomarkers is huge, especially in fields like sarcoma, where conventional 
biomarkers have so far failed to provide accurate diagnostic and prognostic uses (see Section 
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3.1.2.1, Grading of chondrosarcoma tumors and its challenges). In osteosarcoma, there is a 
growing number of publications addressing single or combined miRNA signatures form liquid 
biopsies aiming to improve the diagnostic accuracy of the disease (Raimondi, De Luca et al. 
2017; Wang, Ning et al. 2017). On the other hand, in chondrosarcoma the amount of research 
focused on circulating miRNAs is alarmingly low. In fact, the very first article including 
circulating miRNAs from chondrosarcoma patients was published during the time that this 
thesis was being written (March, 2019) (Asano, Matsuzaki et al. 2019). For all these reasons, 
we believe that miRNAs, and especially circulating miRNAs, hold great promise for the 
discovery of novel and clinically helpful biomarkers in chondrosarcoma. Additionally, other 
than just being used for tumor subtype assessment, tumor-derived miRNAs could be evaluated 













Figure 8: Schematic representation of the possible release mechanisms of miRNAs to the extracellular space. In 
the cytoplasm, miRNAs can be packed within extracellular vesicles which are actively secreted by cells, such as 
exosomes (40–120 nm) and microvesicles (0.1–1 μm). Apoptotic bodies (1–5 μm) are byproducts of apoptotic 
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cells and they also can contain miRNAs in their lumen.  MiRNAs can also circulate in a microparticle-free 
fashion, either in association with high-density lipoproteins (HDL) or bound to RNA-binding proteins (RBP, such 
as AGO). When cells die, these miRNAs may be released passively, but also actively in living cells through 




4 Aim of the PhD thesis 
 
Understanding the molecular mechanisms behind chondrosarcoma progression is of utmost 
importance for the development of targeted therapies. miRNAs play an essential role in cancer 
progression and uncovering their biological contribution and targets is a valuable tool for the 
discovery of novel cancerous genetic drivers. Thus, the first sub-aim of the present thesis was 
to identify deregulated miRNAs –with a focus on miRNAs that belong to the same cluster or 
family- in a cohort of human tumor samples. This included chondrosarcoma specimens of 
different grades as well as benign chondrogenic tumors that can progress towards 
chondrosarcoma. 
The second sub-aim of this work focused on studying the phenotypic contributions of the 
chosen miRNAs to chondrosarcoma malignancy in vitro. Furthermore, we wanted to test if our 
miRNA candidates would also have an in vivo effect. In order to do this, it was necessary to 
firstly address a third sub-aim, being the establishment of a suitable in vivo orthotopic 
chondrosarcoma xenograft model. We tested and compared two-previously reported 
orthotopic mice models in chondrosarcoma based on various parameters, such as tumor 
penetrance, time until tumor initiation and metastatic spread. The fourth sub-aim consisted on 
performing an in vivo study with the chosen orthotopic model for the assessment of the effect 
of the selected miRNAs on tumor growth and metastasis formation.  
As miRNAs exert their biological function by regulating other genes, our fifth sub-aim 
consisted on studying which miR-143/145 direct target(s) are affected from their deregulation, 
and how they (may) contribute to chondrosarcoma malignancy. Lastly, our final and sixth 
sub-aim addressed the following question: Could blood-circulating miRNAs be used as 
diagnostic biomarkers in chondrogenic neoplasms? 
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The results obtained from the third sub-aim are presented in section 5.1 “Additional 



























5.1 Additional Studies:  Establishment of an Orthotopic Chondrosarcoma 
Mouse Model 
Purpose 
To establish a suitable chondrosarcoma xenograft mouse model to study the in vivo effect 
of the selected miRNAs in tumor growth and metastatic disease. For this, we tested two 
reported orthotopic xenograft mouse models in bone sarcomas.  
 
Introduction 
The main advantage of orthotopic cell injections is that they reproduce the original site for 
the development of cancer (Jacques, Renema et al. 2018). For being the best described 
chondrosarcoma models, we aimed to test the intra-osseous (intratibial) and para-osseous 
(paratibial) model. 
In the paratibial model, cancer cells are injected next to tibia. Before that, the periosteum is 
briefly activated by gently scratching its surface with a needle.  On the other hand, the 
intratibial model is based on injecting the cancer cells into the intramedullary cavity. For that, 
it is firstly required to generate a hole with a 21–26G needle in the tibial plateau to give access 







Figure 1: Illustration of the paratibial and intratibial injection approaches. Image adapted from (Uluckan, 




The in vivo study was conducted with the approval of the Ethics Committee of the Canton 
Zurich Veterinary Office, and in accordance with the Swiss Animal Protection Law. 
Immunocompromised 6- to 7-week-old female SCID/CB17 mice were obtained from Charles 
River Laboratories 14 days before tumor cell injection (TCI). Two different cells amounts 
were injected for both tested cells lines (JJ012 and SW1353): 100,000 and 400,000 cells. The 
volume of injection in the intratibial model was 10µL (PBS/0.05% EDTA), whereas for the 
paratibial was 50µL (1:1 PBS/0.05% EDTA and Matrigel). The number of animals per each 
cell line/cell number condition was n=6 for the intratibial and n=7 for the paratibial model. 
Tumor growth was monitored by caliper measurements and X-ray imaging on a weekly 
basis. All mice were sacrificed before they reached a maximum tumor volume of 300 mm3. 
Additionally, as cell lines were equipped with a β-galactosidase gene (Figure 2), we stained 
different organs (lungs, liver, spleen, etc) ex-vivo with X-Gal to determine the quantity of 

















In the intratibial model, we observed a direct effect of the number of injected cells on the 
tumor penetrance rates (16.6% and 83.3% for 100,000 and 400,000 JJ012_LacZ injected cells, 
respectively) (Table 1). We only tested 400,000 cells paratibially as this model is less 
restrictive compared to the intratibial in terms of the maximum volume that can be injected 
due to limited space in the intramedullary cavity. For the same amount of injected cells the 
paratibial and intratibial models showed similar tumor penetrance efficiencies (400,000 cells, 
85.7% and 83.3%, respectively).  
Importantly, no tumors developed during the entire length of the study (4 months) in mice 
that with SW1353_LacZ cells. Previously reported reports have demonstrated that SW1353 
can efficiently develop tumors subcutaneously (Jacques, Renema et al. 2018). Two other 
published works also showed that SW1353 cells can grow intratibially. However, there are 
some differences in the technical approach that might explain the discrepant findings. In one 
of the published studies, cells were previously cultured with Matrigel and then transplanted 
inside the tibia of SCID mice (Horas, Kurth et al. 2012). In the other case holes of 0.35mm in 
diameter where generated in the tibia with a drill, followed by flushing out the bone marrow 
cells in order to create more space for SW1353 cells to grow (van Oosterwijk, Plass et al. 
2015). Although it is very unlikely, the retroviral transduction of SW1353 used in our study to 
generate SW1353 might have had an effect on their ability to form tumors in vivo. 
Noteworthy, the in vitro characterization of LacZ-tagged cells did not detect any differences 
when compared to the parental cell lines (data not shown). This goes in fully agreement with a 
study conducted by our group demonstrating that LacZ expression had no influence on the 
growth of tumors and metastasis formation in osteosarcoma (Arlt, Banke et al. 2011). To our 
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knowledge, there are no published studies that tested the ability of SW1353 cells to grow 






Table 1: Summary of the tumor penetrance rates for different chondrosarcoma cells lines injected intratibially or 
paratibially in SCID mice 
 
Times until tumor appearance 
As it will be described in the next result section (5.2), artificial over-expression of miRNAs 
in chondrosarcoma cells was aimed to be performed in a doxycycline-inducible fashion. 
Therefore, to be able to start the induction of all mice simultaneously, it was crucial for our 
model to develop tumors within consistent time periods. Tumor detection was done by X-ray 
imaging and caliper measurements (Figure 2). Interestingly, mice injected with JJ012_LacZ 
cells paratibially showed both, shorter latency times until tumor appearance and better 
intragroup homogeneities compared to those injected intratibially (Figure 2.A and 2.B). 
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Figure 1: A) X-ray images in both tumor-bearing and control legs at time of tumor appearance (red arrow). B) 
Tumor growth monitored weekly for both models after tumor cell injection (TCI). C) Time until tumor detection 
in both tested models. 
 
Tumor and metastasis features 
Paratibial and intratibial tumors exhibited some typical clinical features of chondrosarcoma, 
such as osteolytic lesions in the bone (Figure 3.A). Tumor size doubled every week on 
average. Importantly, in both models, metastatic lesions were found in the lungs. Not 
surprisingly, all primary tumors were positively stained by X-gal (Figure 3.B). Other organs 
were tested for the presence of metastasis (spleen, liver and heart) but no metastatic lesions 
were found. 







Figure 3: A) Osteolytic lesions (green arrows) seen by X-ray in both tested models (the picture corresponds to a 
paratibial case). B) Primary tumor obtained from a mouse injected intratibially and subsequently stained for X-
gal. Blue areas represent tumor cells bearing the β-galactosidase (LacZ) gene. 
 
Interestingly, intratibial tumors showed a higher metastatic potential than paratibial ones. 
Macrometastases were abundant in the lungs of intratibially injected mice, while rare in 
paratibially injected animals. Similarly, the amount of micrometastases was superior in the 


















Figure 4: A) X-gal stained lungs showing macrometastases (left) or micrometastasis (right) in the lungs of mouse 
intratibially injected with chondrosarcoma cells B) X-gal stained lungs showing macrometastases (left) or 
micrometastasis (right) in the lungs of mouse paratibially injected. 
 
Conclusions 
The present study aimed to compare different orthotopic xenograft chondrosarcoma mouse 
models. We studied two models that are commonly used in the field of bone sarcomas, being 
intratibial and paratibial. Additionally, we evaluated two different human established 
chondrosacoma cell lines, SW1353 and JJ012, and in two different conditions: 100,000 and 
400,000 injected cells.   
Because SW1353 cells did not show signs of growth in any of the conditions tested (even 
several months after the tumor cell injection day), we disregarded them for following studies. 
Taken together, from our work we can conclude that the paratibial model performed better 
than the intratibial in terms of homogeneity of tumor initiation times, which was a 
fundamental factor for the experimental setup to the subsequent study regarding the in vivo 
role of miRNAs in chondrosarcoma. Additionally, from a technical standpoint of view, 
paratibial injections are easier to apply and they are less painful for the animals. We believe 
that cells injected intratibially possibly require creating space in the bone cavity in order to 
grow, resulting in longer periods of time for tumors to develop. 
For the same amount of injected cells, both injection approaches showed similar tumor 
penetrance rates, suggesting that JJ012 cells can grow well in vivo. In addition, the intratibial 
model is more suitable to study the metastatic potential of tumors, for forming more and larger 
metastatic lesions. We believe that for being injected directly in the medullar cavity, cancer 
cells have a better access to vasculature and, therefore, metastasize more efficiently.   
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In conclusion, we selected the paratibial model (400,000 JJ012 injected cells) for showing 
good penetrance rates and, importantly, very regular times of tumor appearance, a 
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Purpose: Chondrosarcoma is the second most frequent bone sarcoma. Due to the inherent 
chemo- and radiotherapy resistance and absence of known therapeutic targets, clinical 
management is limited to surgical resection. Consequently, patients with advanced disease 
face a poor prognosis. Hence, elucidating regulatory networks governing chondrosarcoma 
pathogenesis is vital for development of effective therapeutic strategies. 
Experimental Design: miRNA and mRNA next generation sequencing of different 
subtypes of human chondrogenic tumors in combination with in silico bioinformatics tools 
was performed with the aim to identify key molecular factors. Validation of miRNA levels 
were further determined in a larger cohort of tumor and plasma samples from patients by qRT-
PCR.  The biological relevance of miR-143/miR-145 and their target fascin-1 (FSCN1) was 
studied in in vitro functional assays using chondrosarcoma cell lines with transient/stable 
cluster overexpression or target gene knockdown. Additionally, in vivo effects of miR-
143/miR-145 overexpression were investigated in an orthotopic xenograft mouse model. A 
tissue microarray containing chondrosarcoma patient samples was immunostained and 
analyzed for FSCN1 expression. 
Results: We demonstrate that miR-143/145 cluster expression inversely correlates with 
tumor grade and plays a tumor suppressor role in vitro and in vivo. Circulating miR-145 is 
highlighted as a potential non-invasive diagnostic biomarker. Furthermore, we newly identify 
FSCN1 as a direct cluster target and its knockdown had similar effects as miR-143/145 
overexpression in vitro. Lastly, FSCN1 is a malignancy promoting factor associated with 
aggressive chondrosarcoma progression.  
Conclusions: Our findings underscore miR-143/145/FSCN1 as important players in 




Chondrosarcoma is the second most frequently diagnosed bone sarcoma after osteosarcoma 
(1). It has a broad spectrum of histological appearances, however, conventional 
chondrosarcoma accounts for 90% of all cases. The conventional subtype together with other 
less common chondrosarcoma variants, such as dedifferentiated, mesenchymal and clear cell 
chondrosarcoma belongs to a heterogeneous group of cartilage-producing neoplasms known as 
chondrogenic tumors. The World Health Organization (WHO) recognizes three categories of 
chondrogenic tumors: benign, intermediate and malignant (1). An increasing amount of 
evidence supports that benign tumors (enchondromas and osteochondromas) progress towards 
conventional chondrosarcoma, which is echoed in a challenging radiological and histological 
distinction between them (2).  
In contrast to benign tumors, intermediate chondrogenic tumors (grade I chondrosarcoma) 
are locally aggressive and, although rarely metastatic, they can develop towards malignant 
subtypes that often metastasize (grade II or III and possibly to dedifferentiated 
chondrosarcoma) (3). Chondrosarcoma clinical management is limited to surgical resection, as 
conventional chemotherapy and radiotherapy are largely ineffective (4). Therefore, patients 
with inoperable or pulmonary metastatic disease have a poor prognosis. Although recent 
studies focused on the elucidation of factors contributing to chondrosarcomagenesis and 
progression (5-7), the molecular mechanisms remain poorly understood (8). Therefore, there is 
an urgent need to gain a deeper insight into chondrosarcoma biology in order to develop better 
diagnostic/prognostic tools and new therapeutic strategies that will ultimately improve 
patients’ survival.  
MicroRNAs (miRNAs) are a family of small non-coding RNAs of approximately 20–22 
nucleotides in length (9). They participate in a wide variety of biological processes including 
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cell proliferation, differentiation, migration, apoptosis and others through posttranscriptional 
regulation of gene expression.  In cancer, miRNAs are frequently deregulated and act either as 
tumor suppressors or oncogenes depending on the mRNA targets that they control (10). 
Importantly, miRNA expression profiles can be useful to distinguish tumor subtypes, predict 
patient survival or treatment responses.  Additionally, miRNAs have been found to be 
remarkably stable in biological fluids, and therefore, are regarded  as attractive non-invasive 
biomarkers (11). Several studies have shown involvement of miRNAs in chondrosarcoma and 
have identified targets, e.g. SOX9 and VEGF, known to be deregulated in chondrogenic 
tumors (12, 13). Nevertheless, evidence supporting the functional and clinical relevance of 
miRNAs in chondrosarcoma is still limited. Furthermore, potential diagnostic and prognostic 
values of circulating miRNAs have not been evaluated in cartilaginous tumors so far.  
In the current study, we performed next-generation miRNA sequencing on a panel of 
human chondrogenic tumors with the aim to identify novel miRNAs involved in 
chondrosarcoma pathogenesis. Our findings demonstrate that miR-143-3p and miR-145-5p, 
two miRNAs transcribed as part of the same precursor, inversely correlate with tumor grade 
and play a tumor suppressor role in vitro and in vivo. Importantly, we categorize circulating 
miR-145-5p as a potent diagnostic biomarker for chondrogenic tumor subtypes. Finally, an 
integrative transcriptomic and bioinformatics approach allowed us to elucidate miR-143-
3p/miR-145-5p direct target fascin-1 (FSCN1). Moreover, through tissue microarray analysis 
and loss of function studies we provide evidence that FSCN1 contributes to chondrosarcoma 
malignancy. Altogether, our study uncovers novel regulatory factors in chondrosarcoma 
progression.   
Materials and Methods 
Tissue specimens and patients’ characteristics 
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All human tissue samples were collected between 1997 and 2016 at Balgrist University 
Hospital and University Hospital Zurich (Zurich, Switzerland) in accordance with the 
regulations of the local ethic committee (KEK ZH 2013-0430 and EK10/2007). The 
characteristics of patients with chondrogenic tumors and healthy individuals are summarized 
in Supplementary Tables S1, S2 and S3. For mRNA tumor tissue analysis, 42 specimens were 
collected at surgical resection, snap frozen in liquid nitrogen and stored at -80°C. Plasma 
samples from 42 patients were generated from peripheral blood draws 24 hours before and 
after surgery and kept at -80°C.  The training and validation cohorts included 25 and 17 
samples, respectively. Control blood was collected from 20 healthy individuals. A tissue 
microarray (TMA) block was prepared using tissue samples from 55 chondrosarcoma patients. 
Cell culture  
The human chondrosarcoma cell lines JJ012 and 105KC were kindly provided by S.P. 
Scully (University of Miami Miller School of Medicine, Miami, FL, USA) and SW1353 
(HTB-94) cells were obtained from ATCC. Cells were cultured in DMEM (4.5 g/l 
glucose)/HamF12 (1:1) medium (61965026 and 1765029, ThermoFischer) supplemented with 
10% heat inactivated fetal bovine serum (FBS, 10500, ThermoFischer) at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. The cells were mycoplasma-free. For miRNA 
induction experiments cell culture medium was supplemented with the indicated concentration 
of doxycycline (D9891, Sigma-Aldrich). The cell lines were authenticated by short tandem 
repeat DNA profiling (Microsynth) with a PowerPlex®16HS system (DC2101, Promega) and 
by comparison with the German Collection of Microorganisms and Cell Cultures database. 
Primary cell lines were generated from resections of benign chondrogenic tumors collected at 
Balgrist University Hospital and cultured as described in (14). Three randomly-selected cell 
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lines were used in our study: one enchondroma-derived (#4) and two osteochondroma-derived 
(#5 and #10). 
Plasmid constructs, transient transfection and lentiviral transduction  
In order visualize tumor cells within mouse tissues, chondrosarcoma cells were stably 
transduced with a LacZ gene and selected as described (15). Transient transfection was 
performed according to the manufacturer’s instructions using Lipofectamine RNAiMax 
(13778030, ThermoFischer) and the following miRNA mimics: miR-145-5p (HMI0224), 
miR-143-3p (HMI0221) and scrambled negative control (HMC0002), all purchased from 
Sigma-Aldrich, and used at a final concentration of 8 nM. 
Tetracycline-responsive cells were obtained by lentiviral transduction with pLenti CMV 
rtTA3 Hygro (3rd generation lentiviral reverse tetracycline-controlled transactivator 3), and 
selected with medium supplemented with 400 µg/mL of hygromycin (400051, Merck 
Millipore) during one week. This construct was a gift from Eric Campeau (Addgene plasmid 
26730). pLTR143-5 plasmid containing the miR-143/145 precursor DNA cloned in the 3′ 
UTR of RFP and the empty vector pLTR (EV) were a kind gift from Dr. Alfredo Pagliuca.  
Cells equipped with the LacZ and rTA3 gene were transduced with pLTR143-5 or EV as 
described (16) and RFP cells were flow sorted 72 hours after induction with 1 µg/ml of 
doxycycline. This last step was repeated for a second round of sorting. 
Control cells and cells with stable shRNA-mediated FSCN1 knockdown (sh FSCN1) were 
generated through lentiviral infection with control scrambled shRNA (guide sequence: 
TCCGCAGGTATGCACGCGTG) or a shRNA targeting FSCN1 (guide sequence: 
TTCCAGTTTGAAAGGCAAGGG), purchased at GenomeRNAi. Transduced cells were 
selected with medium supplemented with 1 µg/mL puromycin (A1113803, Gibco). All 
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lentiviral particles were prepared with the Lenti-Pac™ HIV Expression Packaging Kit 
(LT001, GeneCopeia) following the manufacturer’s instructions.  
RNA isolation 
Total RNA isolates (miRNA enriched) from cell lines were obtained with a miRNeasy Mini 
Kit (217004, Qiagen), accompanied by on-column DNase-treatment (79254, Qiagen) 
according to the manufacturer’s protocol. RNA from freshly frozen human or murine tumor 
tissue samples was extracted with a miRNeasy Micro Kit (217084, Qiagen). Between 20 and 
30 mg of frozen tumor tissues were homogenized with TissueLyser LT (Qiagen) and 
processed according to the manufacturer’s protocol. RNA from plasma samples was isolated 
as described previously (17). 
RNA sequencing  
For small RNA expression analysis, libraries were prepared with a TruSeq Small RNA 
Library Preparation Kit (Illumina) from 100 ng of total RNA extracted from eight randomly-
chosen tumor samples (3 benign, 2 intermediate, 3 malignant) with homogenous RNA 
integrity numbers. Paired end sequencing of 100-nucleotide sequences was performed on an 
Illumina HiSeq4000 as a service by the Functional Genomics Center Zurich 
(http://www.fgcz.ch/). For total RNA expression analysis, the library preparation was done in 
the same samples with a TruSeq Stranded Total RNA kit (Illumina) complemented with a 
rRNA depletion step (Ribo-Zero Gold rRNA Removal Kit, Illumina).  To detect differentially 
expressed genes/miRNAs, we used the software package EdgeR. The differential expression 
was assessed using an exact test adapted for over-dispersed data. miRNAs with following 
parameters: |log2FC| ≥ 1.5, P < 0.05 and FDR < 0.3 were considered as differentially 
expressed. Genes showing altered expression (|log2FC |≥ 1) with adjusted (Benjamini and 
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Hochberg method) P < 0.01 were considered differentially expressed. Unsupervised 
hierarchical clustering was done using the Ward2 method. The input genes for sample 
clustering were selected based on the read count standard deviations across the samples. The 
top variable 500 genes were chosen for the final sample clustering. 
Reverse transcription and qRT-PCR 
For miRNA expression analysis, 500 ng of miRNA were reverse transcribed from RNA 
extracts in miScript HiSpec Buffer with a miScript II RT Kit (218161, Qiagen) according to 
the manufacturer’s instructions. For mRNA expression analysis, 1 µg of total RNA was 
transcribed to cDNA with a High-Capacity cDNA Reverse Transcription Kit with RNAse 
Inhibitor (4374966, Applied Biosystems) according to the manufacturer. Quantitative PCR 
conditions and primers used are detailed in Supplementary Materials and Methods. Briefly, 
miRNAs in plasma were corrected to C. elegans miRNA-39 and normalized to miRNA-93 
levels (determined by NormFinder algorithm (18)). miRNAs and mRNA levels in cell lines 
and tumor samples were normalized to the housekeeping RNU6B or GAPDH, respectively. 
In vitro functional assays 
Short-term adhesion of cells to collagen I (C3867, Sigma) or fibronectin (F2006, Sigma 
Aldrich) and soft-agar colony formation assay were performed as detailed in Supplementary 
Materials and Methods. Cell cycle analysis and transwell migration assay were done as 
previously reported (19, 20). 
Paratibial human xenograft chondrosarcoma mouse model 
The in vivo study was conducted with approval of the Ethics Committee of the Canton 
Zurich Veterinary Office, and in accordance with the Swiss Animal Protection Law. 
Immunocompromised 6- to 7-week-old female SCID/CB17 mice were obtained from Charles 
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River Laboratories 14 days before tumor cell injection (TCI), done on day 0 of the experiment. 
For orthotopic TCIs, mice were paratibially injected with 4x105 doxycycline-responsive 
JJ012/lacZ/EV (18 animals) or JJ012/lacZ/miR-143/145 (18 animals) cells in 50 µL of 1:1 
PBS/0.05% EDTA and Matrigel (356234, Corning, 9.0 mg/ml protein concentration) as 
described (21). Primary tumor growth was detectable (by eye, caliper measurement or X-ray) 
four weeks after the TCI and mice were subsequently randomized according to their weight 
into the following four experimental groups: EV (n=7), EV+DOX (n=11), MIR (n=7) and 
MIR+DOX (n=11). Mice were once treated intraperitoneally with either sterile PBS (vehicle 
control) or doxycycline solution (53.3 mg/kg body weight). The mice were thereafter fed with 
doxycycline-supplemented food (625 mg doxycycline/kg) or control food (produced by 
KLIBA NAFAG) until day 61 after TCI, when they were euthanized as reported (22). Tumor 
development monitoring and processing of primary tumor and lung tissue was done as 
described previously (19). Indigo-blue stained pulmonary metastases on the lung surface were 
counted at 4x magnification under a Nikon Eclipse E600 microscope (Nikon Corporation). 
Screening of miRNA targets 
miR-143-3p and miR-145-p potential target genes were investigated with three different in 
silico prediction on-line tools: TargetScan (www.targetscan.org), miRDB 
(http://www.mirdb.org/) and MicroRNA.org (www.microrna.org/microrna). The list of the top 
100 targets predicted by in silico tools was complemented with the mRNA expression data 
obtained by sequencing of patient primary tumor samples. Only genes predicted by the 
bioinformatic analysis and upregulated in malignant chondrosarcoma samples were considered 
for further validation. Finally, we tested for the expression levels of those selected genes in 




Protein extract preparations and Western blot analysis were performed as previously 
described (19). Antibodies used are listed in Supplementary Materials and Methods.  
Luciferase activity assay 
To test the direct interaction between the studied miRNAs and FSCN1, we co-transfected a 
miRNA Target Expression Vector (E1330, Promega) containing the FSCN1 3’-UTR (either 
wild-type or mutated) together with miR-143, miR-145 or control mimics in JJ012 cells and 
we measured the Firefly and Renilla luciferase activities 48 hours later. Detailed protocol is 
reported in Supplementary Materials and Methods. 
Human chondrosarcoma tissue microarray construction and analysis 
Biopsies with histologically confirmed non‐necrotic tumor tissue from surgical specimens 
obtained from 55 chondrosarcoma patients were marked, and two tissue cores per tumor and 
normal bone specimens with a diameter of 0.6 mm were arranged in a tissue array as described 
(23). A 2‐µm section of the tissue array was transferred to an adhesive‐coated slide system 
(Superfrost Plus, ThermoFisher Scientific, Waltham, MA USA), deparaffinized, and stained 
with an antibody against FSCN1 (mouse monoclonal antibody, dil. 1:400; MS-1112-S1, 
ThermoFischer), following standard procedures. The immunostaining analysis was performed 
as previously reported (19).  
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, 
Inc, USA). Statistical significance of differences between the experimental groups was 
determined using a one or two-way ANOVA test with Bonferroni post-test. Student's t test 
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(unpaired) was used in miRNA-mimics and FSCN1 knockdown experiments. The correlation 
of miRNA levels was determined by Pearson correlation analysis. The experiments were 
performed in at least three independent replicates and results are shown as mean ± standard 
error of the mean (SEM). The receiver operating characteristic (ROC) curves were generated 
as described (17). The association between FSCN1 staining (positive/negative) and tumor 
grade in the TMA study was evaluated by the Chi-square test (Fischer’s exact test). The results 
were considered significant when P < 0.05.  
Results 
Sequencing of small RNAs reveals miR-143/145 to be downregulated in chondrosarcoma 
With the aim to identify novel regulators of chondrosarcoma pathogenesis, we analyzed 
both miRNA and mRNA expression profiles in primary tumor tissues collected from patients 
diagnosed with chondrogenic tumors of different malignancies. We applied next-generation 
sequencing to 3 benign chondrogenic tumors, 2 intermediate chondrosarcomas and 3 
malignant chondrosarcomas. Unsupervised hierarchical clustering of mRNA expression 
profiles resulted in a better separation of tumor groups than the same analysis obtained from 
miRNA expression data (Supplementary Fig.S1). Nevertheless, we identified 43 down- (Fig. 
1A and B) and 59 upregulated miRNAs in malignant versus benign tumors (Supplementary 
Fig. S1). In the current study, we focused on downregulated miRNAs that could be potential 
tumor suppressors.  
Among the downregulated miRNAs, our attention was particularly drawn to miR-143-3p 
and miR-145-5p (subsequently referred to as miR-143/145) as the only broadly conserved full 
miRNA cluster/family present within the top hits. We focused on a miRNA cluster, as clusters 
can have a more complex target gene network than single miRNAs (24, 25). Noteworthy, both 
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miRNAs were among the most abundant small RNAs in the samples (Fig. 1C), representing at 
least 9.15% of all retrieved miRNA sequences and further implying their relevance for normal 
cartilage homeostasis.  
In order to validate our finding, we performed miR-143/145 expression analysis in a 
broader panel of benign, intermediate and malignant chondrogenic tumors by quantitative RT-
PCR. Consistent with our sequencing data, miR-143 and miR-145 expression was 
significantly decreased in malignant compared to benign specimens (Fig. 1D). The levels of 
the two miRNAs showed, as expected, a strong linear correlation (Fig. 1E) supporting the fact 
that both molecules are synthesized from the same precursor. We next evaluated miR-143/145 
expression in primary benign tumor-derived cells and established human malignant 
chondrosarcoma cell lines (Fig. 1F). In agreement to what we observed in tumor samples, 
established chondrosarcoma cells lines expressed lower levels of miR-143/145 compared to 
primary cells derived from benign tumors. 
In conclusion, miRNA profiling identified miR-143/145 cluster as a potential regulator of 
chondrosarcoma development. 
Diagnostic value of plasma miR-143 and miR-145 in chondrosarcoma 
Circulating miRNAs are widely investigated as cancer diagnostic markers in various cancer 
types (26). Thus, we next determined the levels of miR-143/145 in the plasma of healthy 
controls and patients with chondrogenic tumors by qRT-PCR (Fig. 2A). The results show a 
significant reduction in the circulating levels of both miRNAs in preoperative patient plasma 
compared to healthy controls, regardless the malignancy. Importantly, levels of miR-143 and 
miR-145 also displayed in the circulation a strong linear correlation (Fig. 2B). To assess the 
potential utility of plasma miR-143/145 levels as a non-invasive diagnostic marker for 
chondrosarcoma, we performed ROC curve analysis using training and validation cohorts as 
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well as their combination (Supplementary Fig. S2). As illustrated in Fig. 2C and D, an analysis 
designed to distinguish patients with malignant chondrogenic tumors from  healthy controls 
yielded AUC values of 0.8813 (95% CI, 0.7601-1.002) and 1.000 (95% CI, 1.000-1.000) for 
miR-143 and mir-145, respectively. Additionally, miR-145 plasma levels proved to be useful 
to differentiate patients with malignant disease from patients with benign tumors with AUC 
value of 0.7578 (95% CI, 0.5869-0.9288; Fig. 2E). We next compared the miR-143/145 levels 
in the circulation of individual patients before and after tumor removal (Fig. 2F). Intriguingly, 
we found a statistically significant increase in the levels of both miRNAs in postoperative 
plasma. 
Thus, our results imply that downregulation of miR143/145 cluster in the bloodstream is 
associated with chondrosarcoma progression. Furthermore, circulating miR-145 can be 
utilized to distinguish patients with different types of cartilaginous tumors. 
miR-143/145 overexpression reduces the oncogenic properties of chondrosarcoma cell 
lines in vitro 
In order to investigate the functional relevance of miR-143 and miR-145 for 
chondrosarcoma malignancy, both miRNAs were artificially upregulated in two established 
chondrosarcoma cell lines, JJ012 and SW1353, using transient or stable overexpression 
systems. For short-term experiments we used the transient transfection approach. Considering 
that constitutive overexpression of a potential tumor-suppressor might lead to complete 
growth arrest or induce counter-selection, we established an inducible lentiviral system of 
stable cell lines which conditionally overexpressed the miR-143/145 cluster in a doxycycline-
dependent manner (16). Overexpression of both miRNAs in the two cell lines following 
transient transfection (Fig. 3A) or doxycycline induction was confirmed via quantitative RT-
PCR (Fig. 3B). Transient transfection of miR-143/145 mimics in JJ012 cells resulted in 
70 
 
increased attachment to collagen (P < 0.05) and fibronectin (P > 0.05) (Fig. 3C), two 
extracellular matrix ligands highly abundant in the cartilage. There were no apparent 
differences in the proliferation and migration rates of both chondrosarcoma cell lines upon 
miR-143/145 overexpression (data not shown). However, a flow cytometric analysis of cell-
cycle progression upon miR-143/145 cluster overexpression revealed a G1 cell-cycle arrest in 
JJ012 cells (Fig. 3D). We next studied the effects of long-term miR-143/145 induction on 
anchorage-independent growth using a soft-agar assay and found that both chondrosarcoma 
cell lines, upon induction of cluster upregulation, have a reduced ability to form colonies 
compared to control cells (Fig. 3E).  
Collectively, the in vitro findings presented here implicate that miR-143/145 cluster 
overexpression reduces the malignant properties of the investigated chondrosarcoma cell lines 
by affecting adhesion, cell cycle progression and colony forming capacity. 
miR-143/145 overexpression impairs tumor growth in vivo 
Based on the observation that forced expression of the miR-143/145 cluster decreases the 
oncogenic features of chondrosarcoma cell lines in vitro, we subsequently explored whether 
the cluster overexpression has an impact on primary tumor progression and metastasis 
development in vivo using a xenograft orthotopic mouse model. To this end, JJ012/LacZ cells 
stably transduced with doxycycline-inducible expression vectors carrying either empty vector 
alone (EV) or miR-143/145 (MIR) were paratibially injected into immunocompromised SCID 
mice. Doxycycline or control treatment was started four weeks after tumor cell injection, 
namely as soon as the primary tumor formation was detectable. As expected, miR-143/145 
induction caused a substantial inhibition of tumor growth, as reflected by significantly smaller 
relative tumor volumes in the MIR+DOX group of animals compared to the control EV, 
EV+DOX and MIR groups (Fig. 4A). Of note, primary tumor development, monitored by X-
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Ray imaging over time, was associated with increasing osteolytic bone lesions in all the 
experimental groups (Fig. 4B). The efficacy of our doxycycline-inducible expression system 
was also confirmed in vivo by determining miRNA levels in tumors harvested from animals at 
the end of the experiment (Fig. 4C). In line with the in vitro findings, the induction of miR-
145 was considerably more efficient than the miR-143 expression induction. It is, however, 
worth mentioning that a certain leakiness of the transgene expression is present in the absence 
of doxycycline. 
Importantly, we found an inverse correlation between miRNA levels and tumor volume 
(Fig. 4D). We then investigated whether miR-143/145 cluster interferes with the metastatic 
dissemination of chondrosarcoma cells. In contrast to its potent tumor-suppressive activity, 
miR-143/145 cluster did not significantly impact the number of X-Gal stained pulmonary 
metastases (Fig. 4E and F). Noteworthy, we observed a tendency towards a decreased number 
of metastatic nodules in the lungs of animals orthotopically injected with JJ012/LacZ/miR-
143/145 cells, regardless of doxycycline treatment, compared to animals bearing 
JJ012/LacZ/EV-derived tumors.   
Taken together, our in vivo data clearly demonstrate that the miR-143/145 cluster inhibits 
primary tumor growth without affecting the metastatic spread of chondrosarcoma cells.  
Identification of FSCN1 as a direct miR-143/145 cluster target in chondrosarcoma 
To elucidate the underlying mechanisms of tumor-suppressive effects of miR-143/145 
cluster, we developed a combinatorial analysis strategy to identify putative miR-143/145-
regulated gene targets. The list of targets predicted by three in silico tools (TargetScan, 
miRDB and microrna.org) was complemented with the mRNA expression data obtained by 
sequencing of patient primary tumor samples. Taking into account that miRNAs primarily 
negatively regulate their target’s mRNA and/or protein expression, we hypothesized that 
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levels of the miRNAs in clinical samples should inversely correlate with the levels of putative 
target genes. Therefore, only genes predicted by the bioinformatic analysis and upregulated in 
malignant chondrosarcoma samples were considered for further validation (Fig. 5A). The 
same workflow was applied for each prediction tool, and we shortlisted our candidates to only 
those genes identified as targets by all three databases (Fig. 5B). The normalized counts of the 
selected genes in tumor samples (4 for miR-143 and 4 for miR-145) are summarized in a 
heatmap (Fig. 5C). To experimentally validate our target screening approach, qRT-PCR 
expression analysis of the eight candidate genes in control cells and transiently overexpressing 
miR-143/145 JJ012 and SW1353 cell lines was performed (Fig. 5D). Among all tested genes, 
only FSCN1 was significantly downregulated in both cell lines in response to miR-143 and 
miR-145 mimics. Next, we analyzed FSCN1 protein expression in control and miR-143 or 
miR-145 overexpressing cells and found that FSCN1 levels were markedly reduced by both 
individual miRNAs in both cell lines (Fig. 5E). The same was true in cells with stable miR-
143/145 overexpression (Supplementary Fig. S5). In line with these findings, FSCN1 protein 
expression inversely correlated with miR-143/145 levels in primary tumors of doxycycline-
treated animals (Supplementary Fig. S5). Overall, we demonstrated that miR-143/145 
negatively regulated FSCN1 expression both in vitro and in vivo. In order to validate FSCN1 
as a direct target of miR-143, miR-145 or both, we constructed a luciferase reporter containing 
the 3’-UTR region of the FSCN1 gene. According to TargetScan the FSCN1 3’UTR contains 
one and four conserved miRNA binding sites for miR-143 and miR-145, respectively. The 
results show that miR-143 and miR-145 significantly inhibited the luciferase activity of wild-
type reporter in JJ012 cells when compared with the negative control. Importantly, 
mutagenesis of all conserved seed sites within the FSCN1 3’-UTR region abolished the 
inhibitory effect of miR-143 and miR-145 on the luciferase activity (Fig. 5F). 
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Collectively, our screening strategy followed by luciferase assays identified and confirmed 
FSCN1 as a direct target of both miR-143 and miR-145 in chondrosarcoma.  
FSCN1 contributes to the malignant properties of chondrosarcoma cells in vitro and is 
upregulated in more aggressive human chondrosarcoma tumor specimens 
FSCN1, highly expressed in many carcinomas, was shown to contribute to their 
aggressiveness (27). To evaluate the function of FSCN1 in chondrosarcoma, we first 
investigated the phenotypic effects of its downregulation in chondrosarcoma cells. The 
efficacy of stable shRNA-mediated FSCN1 knockdown was confirmed on mRNA and protein 
levels in both JJ012 and SW1353 cell lines (Fig. 6A and B). FSCN1 silencing did not 
influence adhesion to different ECM ligands or cell proliferation rates in 2D cell culture (data 
not shown). Interestingly, cell cycle progression analysis revealed a similar effect as 
previously observed in miR-143/145 overexpressing cells (Fig. 6C). Furthermore, although the 
total number of colonies grown in soft agar was not affected, both JJ012 and SW1353 cells 
with FSCN1 knockdown formed significantly smaller colonies in size compared to control 
cells (Fig. 6D). Finally, in agreement with the described role of FSCN1 in carcinomas, the 
migratory capacity of chondrosarcoma cells was significantly inhibited upon FSCN1 silencing 
(Fig. 6E). Considering the negative correlation between miR-143/145 and FSCN1 expression 
as well as the contribution of FSCN1 to the malignant phenotype of chondrosarcoma cells in 
vitro, we postulated that FSCN1 expression could be linked with the clinicopathological 
features of human chondrosarcoma. To test our hypothesis, we performed 
immunohistochemical staining for FSCN1 protein expression on a tissue microarray sections 
containing tumor specimens isolated from 55 patients diagnosed with Grade I, Grade II or 
Grade III chondrosarcoma (Fig. 6F). Indeed, the proportion of FSCN1 positively stained 
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samples in grade III specimens (100%) was significantly higher than in grade I (39%) and 
grade II (48%) (P < 0.05). 
In summary, these results indicate that FSCN1 plays a tumor-promoting role and is 
associated with aggressive chondrosarcoma progression.  
Discussion 
The absence of efficient treatment options for chondrosarcoma patients with nonresectable 
or metastatic disease highlights the urgency for the discovery of novel therapeutic targets. 
Unravelling the mechanisms that govern tumor initiation and progression is therefore crucial 
in order to develop successful disease management and improve patient survival. With the 
intention to elucidate novel players in chondrosarcoma progression, we aimed at the 
identification of aberrantly expressed miRNAs by performing the Next-gen miRNA 
sequencing study in a panel of human chondrogenic tumors. In the past years, multiple 
individual deregulated miRNAs have been implicated in chondrosarcoma progression (28-30). 
Our data confirmed prior reports of dysregulation of several miRNAs (such as miR-200b, 
miR-125, miR-335, miR-183, miR-138, miR-222) (12, 31). In contrast to previously reported 
studies, our work focused on families or clusters of miRNAs, groups of commonly co-
transcribed miRNAs that can jointly exert a more robust target gene regulation than single 
miRNAs (24, 25). We identified miR-143/145 as the only conserved downregulated miRNA 
cluster in chondrosarcoma that inversely correlated with tumor aggressiveness. Reduced levels 
of miR-143 or miR-145 have been reported in other tumor entities, and both molecules are 
generally acknowledged as tumor suppressors (32, 33). Our results are consistent with the 
findings recently published showing miR-145 to be downregulated in chondrosarcoma (34), 
however, the authors analyzed only a small cohort consisting of five clinical samples without 
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investigating the functionality of the miRNA. Importantly and in contrast to previous reports, 
our results are strengthened by an analysis of a considerably larger (42 samples) cohort. 
Furthermore, we provide a foundational piece of evidence on the use of circulating miRNAs 
as non-invasive biomarkers in chondrosarcoma, a valuable diagnostic tool in other sarcoma 
types (17). Both miRNAs were significantly downregulated in preoperative plasma of patients 
compared to healthy individuals. Strikingly, miR-145 plasma levels were lower in 
chondrosarcoma patients than in subjects with benign chondrogenic neoplasms (data 
confirmed in a validation cohort), suggesting that lower miR-145 is associated with a more 
aggressive disease, as seen for other miRNAs (35, 36). Given the observed power of 
circulating miR-145 alone to discriminate different chondrogenic tumor subtypes, we suggest 
that it can be useful as an non-invasive biomarker to improve chondrosarcoma diagnosis, 
which is a very challenging task (2). We believe that miR-145 in combination with additional 
deregulated miRNAs or other clinical features, including grading based on imaging (37), could 
facilitate an accurate assessment of tumor type, and potentially be translated into appropriate 
clinical management.  
The fact that we observed miR-143/145 levels restoration upon tumor removal suggests that 
chondrosarcoma cells could regulate miR-143/145 secretion in neighboring cells (38). 
However, considering the short time period of  sample collection after surgery, we cannot 
exclude that this effect was caused by other tissues possibly reacting to the surgical 
intervention, such as vascular smooth muscle cells (39). Therefore, later time points after 
resection as well as multicenter clinical validation in a novel cohort should be envisaged.  
Subsequently, we sought to delineate the role of miR-143/145 cluster in chondrosarcoma 
cell biology by performing in vitro and in vivo functional studies upon miRNA expression 
manipulation. Our in vivo study employing an orthotopic xenograft model is the first 
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demonstration of the tumor-suppressive role of miR-143/145 in chondrosarcoma. Our findings 
reflect much of the literature regarding miR-143/145 roles in different cancer types (16, 40).  
Furthermore, the inhibition of primary tumor growth observed in vivo is in line with our in 
vitro data, where we show that miRNA enforced upregulation led to altered distribution of cell 
cycle phases and negatively affected the ability of cells to grow in an anchorage-independent 
manner. Cluster overexpression also increased the affinity of cells for extracellular matrix 
components abundant in the human cartilage, which could provide an advantageous ability of 
low-expressing miR-143/145 cells to escape the primary tumor site. On the other hand, we 
were not able to draw major conclusions regarding the association of miR-143/145 with 
metastasis formation, which has been previously reported in other tumor models (41) and 
would be of additional clinical relevance given the known burden caused by metastasis in 
chondrosarcoma patients (42). Our observations suggest that miR-143/145 do not affect the 
initial steps of metastasis. However, we could not assess the effects on the colonization and 
outgrowth in the lungs because, in our setting, most of the lesions were only visible under the 
microscope.    
Another key finding of our work is the identification of FSCN1 as a direct target of miR-
143/145 cluster in chondrosarcoma. FSCN1 is a gene that encodes an actin-bundling protein 
involved in the formation and functioning of cell protrusions relevant for cell motility and 
invasion (43). Evidence obtained from numerous cancer types has highlighted that miR-143 
and miR-145 target FSCN1 (32, 44). In the current study, we found that miR-143 and miR-
145 function as negative regulators of FSCN1, as we observed reduced FSCN1 expression 
following miR-143/145 upregulation and the direct interaction was confirmed in a luciferase 
assay. FSCN1 expression is frequently increased in carcinomas and is associated with a high 
risk of mortality and metastasis (27), making it a good prognostic marker in some epithelial 
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cancers (45). In contrast, only few studies have addressed the role FSCN1 in sarcomas (46, 
47). To our knowledge, the here presented work is the first study investigating FSCN1 in 
chondrosarcoma. Our sequencing data indicated that FSCN1 mRNA is abundant in tumor 
specimens (data not shown) and an immunostaining analysis of a chondrosarcoma TMA 
revealed that the number of samples positively stained for FSCN1 increases with tumor grade. 
Similarly to other cancer models (48), depletion of FSCN1 in chondrosarcoma cells reduced 
their migratory capacity. FSCN1 knockdown cells induced a G1-phase cell cycle arrest and 
decrease in colony size in soft agar. Considering the fact that FSCN1 silencing only partially 
phenocopied the effects of miR-143/145 overexpression, we cannot exclude the possibility 
that the cluster mediates its function through downregulation of additional targets in 
chondrosarcoma. Nevertheless, we highlight FSCN1 as a novel oncogenic factor and an 
attractive therapeutic target in chondrosarcoma. It would be of great interest to test the 
efficacy of small molecule inhibitors of FSCN1 in future studies (49, 50).  
Altogether, our study revealed that integrative miRNA-mRNA analysis in combination 
with in silico tools is a powerful and a robust approach for the discovery of chondrosarcoma 
regulators. We demonstrated that miR-143/145 cluster serves as a tumor-suppressor in 
chondrosarcoma. Both miRNAs exert their antitumor functions, at least in part, through a 
coordinated regulation of FSCN1 that we subsequently recognized as a malignancy promoting 
factor in chondrosarcoma pathogenesis. Moreover, we newly identified circulating miR-145 as 
a promising non-invasive biomarker. In conclusion, our findings underscore miR-
143/145/FSCN1 as important players in chondrosarcoma progression. Restoration of 
miR145/145 levels in tumors or direct FSCN1 targeting are attractive potential options for 
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Figure 1.  The miRNA cluster miR-143/145 is downregulated in chondrosarcoma patient 
specimens. A, Volcano plot depicting the differential expression of miRNAs in malignant 
compared to benign chondrogenic tumors. Gray dots represent significantly up or 
downregulated miRNAs meeting the thresholds of log2 fold change above 1.5 and under −1.5, 
P < 0.05 and FDR < 0.30. B, List of the top downregulated miRNAs in malignant 
chondrosarcoma specimens (selected miRNAs are shown in bold). C, Normalized expression 
levels of top 500 most expressed miRNAs  in tumor samples; the dotted line represent the 1:1 
ratio, selected miRNAs (marked in black) are downregulated (bellow the line) and highly 
abundant. D, Relative miR-143 (left) and miR-145 (right) expression in human benign (n=17), 
intermediate (n=7) and malignant (n=18) chondrogenic primary tumor samples. The data are 
normalized to RNU6B levels. E, Pearson correlation between miR-143 and miR-145 levels in 
tumor samples (ΔCT values shown). F, miR-143 and miR-145 expression levels in primary 
tumor-derived cells and indicated established human chondrosarcoma cells lines. Values in D 
represent the median ± SEM, and values in F the mean ± SEM of miRNA expression. *, P < 
0.05; ***, P < 0.001. 
 
Figure 2. Diagnostic performance of miR-143/145 levels in the plasma of patients bearing 
chondrogenic tumors. A, Expression levels of miR-143 (left) and miR-145 (right) in the 
plasma of healthy subjects (n=20) and patients with benign (n=16), intermediate (n=10) and 
malignant (n=16) tumors depicted in dot plots (grey represents training and black validation 
cohort).  miR-93 and c-39 were used as normalization controls. B, Pearson correlation of miR-
145 versus miR-143 levels in plasma from all patients and healthy controls (ΔCT values 
shown). C, ROC curve plotted to distinguish healthy subjects from patients with malignant 
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chondrogenic tumors using plasma miR-143 or miR-145 (D) expression levels. E, ROC curve 
plotted to differentiate patients with benign from patients with malignant chondrogenic tumors 
using plasma miR-145 expression levels. F, miR-143 (left) and miR-145 (right) levels in 
plasma from the individual patients taken before (Pre-op) and after (Post-op) tumor removal 
(benign, n=9; intermediate, n=5; malignant, n=9). *, P < 0.05; ***, P < 0.001. 
 
Figure 3. The miR-143/145 cluster overexpression exerts tumor-suppressive effects in 
chondrosarcoma cells in vitro. A, Relative miR-143/145 expression in indicated 
chondrosarcoma cell lines 48 hours upon transient transfection with miRNA or non-specific 
scrambled mimics (control). Results are presented as fold change over the control. B, Relative 
miR-143/145 expression in stably-transduced JJ012 (left) and SW1313 (right) cells 48 hours 
after induction with doxycycline (DOX). Fold change of miRNAs expression was normalized 
to the levels in DOX-induced cells carrying only the empty vector (EV). C, Short-term 
adhesion (% of seeded cells) to collagen or fibronectin of JJ012 cells, transiently transfected 
with miR-143/miR-145 or non-specific scrambled control. D, Cell cycle distribution (% of 
total cell population) of JJ012 cell line, assessed by flow cytometric analysis of propidium 
iodide-stained cells, 48 hours after miR-143/miR-145 or non-specific scrambled mimics 
transient transfection. E, Representative images (left panel) and quantification of crystal 
violet-stained colonies grown in a soft-agar assays of miR-143/145 DOX-induced or control 
(EV) stably transduced chondrosarcoma cell lines (right panel) after 4 weeks in culture. All 
values represent the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01; 




Figure 4. miR-143/145 overexpression inhibits tumor growth in vivo. A, Primary tumor 
growth over time monitored by caliper measurements of the tumor volume at indicated time 
points in SCID mice after paratibial injection of JJ012/lacZ cells containing stably integrated 
empty vector (EV) or miR-143/5 (MIR) doxycycline-inducible expression constructs. 
Following tumor detection, at day 28 after tumor cell injection (TCI), DOX or control 
treatment was introduced. EV (n=7) and MIR (n=7) groups of mice were fed with control 
food, whereas EV+DOX (n=11) and MIR+DOX (n=11) groups were fed with DOX-
supplemented food. Values represent mean ± SEM fold change in tumor volume normalized to 
the tumor-bearing leg volume in individual mice measured on the day of DOX treatment 
initiation. B, Representative X-Ray images of tumor bearing legs in indicated groups of 
animals taken at specified time points after tumor cell injection. C, miR-143/miR-145 
expression levels in primary tumor tissue extracts from 25 randomly selected animals of 
designated experimental groups harvested at the end of the experiment. Values are normalized 
to mean miR-143/145 expression in the control (EV+DOX) group and expressed as mean ± 
SEM fold change. D, Pearson correlation between miR-143 and miR-145 levels (-ΔCT values 
shown) and the primary tumor volumes of 25 randomly selected mice. E, ex vivo 
quantification of X-Gal stained JJ012/lacZ/- derived pulmonary metastases. The data indicate 
the numbers of metastases on the whole lung surface of individual mice belonging to the 
indicated groups. F, Representative image of X-Gal stained JJ012/lacZ/- cell line-derived 
micrometastasis in a lung section observed under the microscope (4X magnification); arrows 
indicate the micrometastatic lesions. ns, no significance; *, P < 0.05; ***, P < 0.001. 
 
Figure 5.  Identification of novel miR-143 and miR-145 target genes in chondrosarcoma. A, 
Schematic illustration of the strategy for selecting candidate target genes of miR-143 and miR-
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145 in chondrosarcoma  B, Venn diagram displaying the number of miR-143 (left) and miR-
145 (right) putative target genes, predicted by the indicated in silico platform tools. Numbers 
in black refer to unique targets of a particular platform, while numbers in white to targets 
predicted by two or three platforms. C, Heat-map depicting differential expression of the 8 
selected miR-145 and miR-143 targets obtained by mRNA sequencing in tumor samples. Red 
color represents high relative expression levels and the blue color low expression. D, mRNA 
expression levels of putative miR-143/145 targets in JJ012 (left panel) and SW1353 cells 
(right panel) transiently transfected with miR-143/145 or non-specific scrambled control 
mimics determined by qRT-PCR. E, Western blot analysis of FSCN1 protein expression in 
whole cell extracts obtained from indicated cells transiently transfected with miR-143/145 or 
non-specific scrambled control (NC). Actin was used as a loading control. F, The human 3′ 
UTR of FSCN1 containing wild-type or mutated miR143/145 binding sites was cloned into 
the pmirGLO vector. Luciferase reporter constructs were transfected into JJ012 cells together 
with the indicated miRNA mimics and luciferase activity was measured after 48 hours. Firefly 
luciferase activity was normalized to Renilla luciferase activity. Values in D and F represent 
the mean ± SEM of three independent experiments. **, P < 0.01; ns, no significance. 
 
Figure 6. FSCN1 contributes to in vitro oncogenic potential of chondrosarcoma cell lines and 
is associated with aggressiveness in human patient samples. A, FSCN1 mRNA expression in 
indicated chondrosarcoma cell lines upon stable shRNA-mediated knockdown (sh FSCN1). 
Expression levels are relative to GAPDH and normalized to negative control cells bearing 
scrambled shRNA (NC). B, Western blot analysis of total FSCN1 protein expression in whole 
cell extracts of the indicated chondrosarcoma cell lines. Actin was used as a loading control. 
C, Cell cycle was analyzed by flow cytometry. The graph represents cell cycle distribution (% 
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of total cell population) of specified chondrosarcoma cell lines. D, Representative images of 
crystal violet-stained colonies grown in soft-agar assays after 4 weeks in culture (left panel). 
The mean colony size (relative to control cells) of denoted cell lines (right panel). E, 
Transwell migration of indicated cells lines 24 hours after seeding. F, Representative images 
of chondrosarcoma tumor tissue microarray sections showing entire spots (upper panel) with 
nondetectable (left), moderate (middle), and intense (right) FSCN1 immunostaining. The 
proportion of negative (neg) and positive (pos) FSCN1 staining in chondrosarcoma clinical 
samples with different grading (lower panel). Values in A, C, D and E represent the mean ± 
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hsa-miR-455-5p 4.21 0.0000109 
hsa-miR-140-3p 3.66 0.0000165 
hsa-miR-455-3p 4.14 0.0000445 
hsa-miR-210-3p 3.05 0.000144 
hsa-miR-346 4.22 0.000145 
hsa-miR-138-5p 3.52 0.000172 
hsa-miR-124-3p 4.9 0.000218 
hsa-miR-675-3p 3.61 0.000291 
hsa-miR-140-5p 2.9 0.000369 
hsa-miR-149-5p 2.96 0.000718 
hsa-miR-935 4.53 0.000948 
hsa-miR-210-5p 3.05 0.00115 
hsa-miR-26a-1-3p 3.38 0.00141 
hsa-miR-433-3p 4.38 0.00198 
hsa-miR-483-3p 3.07 0.00228 
hsa-miR-138-1-3p 3.71 0.00242 
hsa-miR-410-3p 3.34 0.00464 
hsa-miR-574-3p 2.13 0.00791 
hsa-miR-379-3p 3.17 0.00892 
hsa-miR-203a-3p 2.36 0.00917 
hsa-miR-6511b-3p 2.23 0.0093 
hsa-miR-203b-5p 2.36 0.00936 
hsa-miR-450a-2-3p 2.39 0.0101 
hsa-miR-375 2.86 0.0109 
hsa-miR-487b-3p 3.19 0.0128 
hsa-miR-887-3p 2.03 0.0133 
hsa-miR-377-5p 2.88 0.0136 
hsa-miR-493-5p 2.93 0.0142 
hsa-miR-431-5p 3.38 0.0143 
hsa-miR-92b-5p 2.26 0.0151 
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hsa-miR-548h-5p 3.1 0.0167 
hsa-miR-323a-3p 3.01 0.0168 
hsa-miR-877-5p 2.04 0.0172 
hsa-miR-654-5p 3.21 0.0175 
hsa-miR-432-5p 3.29 0.0181 
hsa-miR-323b-3p 2.61 0.0185 
hsa-miR-329-3p 2.96 0.0189 
hsa-miR-495-3p 2.87 0.0193 
hsa-miR-320b 1.87 0.0227 
hsa-miR-485-3p 3.05 0.0236 
hsa-miR-103a-2-5p 2.09 0.024 
hsa-miR-1180-3p 1.94 0.0255 
hsa-miR-411-3p 2.92 0.0258 
hsa-miR-543 2.7 0.027 
hsa-miR-6511a-3p 1.98 0.0271 
hsa-miR-153-3p 2.26 0.0279 
hsa-miR-493-3p 2.75 0.0295 
hsa-miR-1296-5p 1.7 0.03 
hsa-miR-183-5p 1.88 0.0346 
hsa-miR-23b-3p 1.76 0.0351 
hsa-miR-668-3p 2.83 0.0397 
hsa-miR-134-5p 2.33 0.0407 
hsa-miR-487a-3p 2.73 0.0412 
hsa-miR-337-3p 2.66 0.0419 
hsa-miR-3687 2.53 0.045 
hsa-miR-6894-3p 1.89 0.047 
hsa-miR-370-3p 2.41 0.0481 
hsa-miR-127-3p 2.16 0.0491 
hsa-miR-483-5p 1.76 0.0493 
 
Supplementary Figure S1: Sample clustering based on mRNA/miRNA expression 
signatures and miRNA differentially expression analysis. A, Nonsupervised hierarchical 
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clustering analysis based on the mRNA or miRNA (B) expression profiles in the sequenced 
tumor samples (3 benign, 2 intermediate, 3 malignant). The input genes for sample clustering 
were selected based on the read count standard deviations across the samples. Top most 
variable 500  genes/miRNAs were chosen for the final sample clustering. C, List of miRNA 


































Supplementary Figure S2: ROC curve analysis of the training cohort, validation cohort and 
their combination for miR-145 (top) and miR-143 (bottom). B, benign; I, intermediate; 
M=malignant; *, P < 0.05.  
miR-145  Training  Validation  Combined 
Comparison AUC p-value AUC p-value AUC p-value 
Healthy vs B 0.8833 *0.0048 0.9714 *0.00128 0.9203 *<0.0001 
Healthy vs I 0.8600 *0.027 1.0000 *0.00221 0.9200 *0.00022 
Healthy vs M 1.0000 *0.0001 1.0000 *0.00221 1.0000 *<0.0001 
B vs I 0.6000 0.5485 0.8286 0.0618 0.5875 0.4606 
B vs M 0.6768 0.1837 0.9143 *0.0185 0.7578 *0.0129 
I vs M 0.8727 *0.02025 0.6400 0.4647 0.6813 0.1265 
miR-143  Training  Validation  Combined 
Comparison AUC p-value AUC p-value AUC p-value 
Healthy vs B 0.7889 *0.0338 0.9143 *0.00467 0.85 *0.00036 
Healthy vs I 0.7600 0.1114 1.0000 *0.00221 0.905 *0.00036 
Healthy vs M 0.8000 *0.0201 0.9600 *0.00486 0.8813 *0.0001 
B vs I 0.6222 0.4634 0.8857 *0.0284 0.6125 0.3428 
B vs M 0.5354 0.7903 0.7714 0.1229 0.5938 0.3658 
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Supplementary Figure S5. 



















Supplementary Figure S5: FSCN1 expression in miR-143/145 overexpressing cells in 
vitro and in vivo. A, Relative FSCN1 mRNA expression in stably-transduced chondrosarcoma 
cells 48 hours after induction with doxycycline (DOX). Fold change of mRNAs expression 
was normalized to the levels in DOX-induced cells carrying only the empty vector. B,   
Western blot analysis of FSCN1 protein expression in whole cell extracts obtained from 
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indicated cells induced with DOX for 48 hours. Actin was used as a loading control. C, 
Western blot analysis of FSCN1 protein expression in whole cell extracts obtained from 
primary tumor tissue of five different animals of each Dox-treated group. GAPDH was used as 
a loading control. D, Pearson correlation between miR-143 (left) or miR-145 (right) levels in 
murine primary tumor samples and relative amounts of FSCN1 (quantified by densitometric 















Supplementary Table S1. Clinical characteristics of patients diagnosed with chondrogenic 
tumors (primary tumor tissue samples). 
  
Variable Benign  Intermediate Malignant 
Number 17 7 18 
Age (years) 
≤ 20 4 1 0 
20-40 8 3 4 
41-69 5 2 9 
≥70 0 1 5 
Gender 
Male 11 5 8 
Female 6 2 10 
Tumor site 
Femur 4 2 7 
Tibia 3 1 0 
Humerus 3 1 1 
Scapula 4 2 3 
Pelvis 1 0 6 
Other 2 1 1 
Stage of disease 
Localized 17 7 12 
Metastatic 0 0 6 
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Supplementary Table S2. Characteristics of healthy subjects and patients with chondrogenic 
tumors (plasma samples). 
 
Variable Healthy subjects Discovery cohort Validation cohort 
Number 20 25 17 
Age (years) 
Mean 37.2 39.3 43.7 
SD 12.4 17.6 19.2 
Gender 
Male 13 12 13 
Female 7 13 4 
Tumor type 
Benign 9 7 
Intermediate 5 5 
Malignant 11 5 
Tumor site 
Femur 7 3 
Tibia 3 2 
Humerus 1 4 
Scapula 5 4 
Pelvis 4 3 
Other 5 1 
Stage of disease 
Localized 21 16 





Supplementary Table S3. Clinical characteristics of chondrosarcoma patients (TMA study). 
 
Variable Grade I Grade II Grade III 
Number 23 25 7 
Age (years) 
≤ 20 5 0 0 
20-40 11 10 0 
41-69 6 10 6 
≥70 1 5 1 
Gender 
Male 15 13 4 
Female 8 12 3 
Tumor site 
Femur 4 8 0 
Tibia 1 0 0 
Humerus 3 1 0 
Scapula 1 2 3 
Pelvis 5 7 3 
Thorax 3 0 1 
Other 6 7 0 
Stage of disease 
Localized 23 21 5 





Supplemetary Table S4. List of primers utilized for Real-Time PCR.  
Gene name Fw Primer (5'-3') Rev primer (5'-3') 
FAM135A TAG TGT AGA AGA AGA GGA TGG T AAG ACG ATC AGT CAT GCT AT 
UBE2E3 ACC ACT GCT AAG TTA TCC ACT A ACA CCA CCT TCA TAT ACA GAA C 
HELLS CAT GTT TGG ATC CAG TGA GAA TCC ACC TCT GGC TGT AT 
FSCN1 GCAAGGACGAGCTCTTT  TTGGCAGACAGGTCCATAC  
GOLM1 CCA ACC TGG AGA GGA AGT CTG TCT CTG GTC GTT GTT T 
SRGAP2 CAC CAA GGA CCA GCA AT TCT TCC TGA GTC CTC GC 
MPZL2 GCT CTA ACA GTG ACC TGG TTC CCA TCC CAA GAC ACC C 
MSI2 CAG AGG GTT TGG CTT TGT CA CAT GGT GTA AGG CAG TCC 
GAPDH AAGGCTGGGGCTCATTTGCAGG AGTTGGTGGTGCAGGAGGCA 
 
 
Supplementary Table S5. List of primer used for site-directed mutagenesis in the specified 
miRNA seeding site at the FSCN1 3’-UTR. 
Position in UTR (nt) Fw Primer (5'-3') Rev primer (5'-3') 
miR-143 (1059-1065) ACACTCTGGGTGTCCTGGTCTTTTATTTTTTG CTAGCATGTCGGGGACGGGACG  
#1 miR-145 (116-123) ccaaACCCCAGAGAAAACGGTG  tcttTGAAAGGCAAGGGGGCTT   
#2 miR-145 (377-384)  ccaaTCTCTTGCCCCTCCCAGC tcttACACTACACGCCCAGGGC 
#3 miR-145 (729-735 ) CCTAGCCTGAgaccAAGCAGAAAATGAC GTGAAAGGAAAGAGGAGG 












Supplementary materials and methods 
 
Reverse transcription and qRT-PCR 
For miRNA expression analysis, 500 ng of miRNA were reverse transcribed from RNA 
extracts in miScript HiSpec Buffer with the miScript II RT Kit (218161, Qiagen) according to 
the manufacturer’s instructions. After cDNA synthesis, the samples were diluted in 100 µL of 
water and 1 µL was then used as substrate for qPCR. Quantitative PCR was done using the 
miScript SYBR Green PCR Kit (218073, Qiagen) according to the manufacturer’s 
instructions. The universal reverse primer provided in the kit was used in all reactions in 
combination with the following miScript Primer Assays (Qiagen) forward primers: Hs_RNU6-
2_11 (MS00033740), Hs_miR-145_1 (MS00003528), Hs_miR-143_1(MS00003514), 
Hs_miR-128_1(MS00008582), Hs_miR-93_1(MS00003346), Hs_miR-214_2(MS00031605), 
Hs_miR-210_1(MS00003801), Hs_miR-16_2(MS00031493), Hs_miR-
593*_1(MS00010283), Hs_miR-21*_1 (MS00009086), Hs_miR-141_1(MS00003507), 
Hs_miR-200a_1(MS00003738), Hs_miR-429_1(MS00004193). The PCR reactions were run 
on an Applied Biosystems Cycler under the following cycling conditions: initial denaturation 
at 95°C for 10 minutes, followed by 40 PCR cycles at 95°C for 15 seconds, 55°C for 30 
seconds and 70° for 40 seconds. The levels of the investigated miRNAs in plasma samples 
were corrected for miRNA extraction efficiency, determined with the spiked-in C. elegans 
miRNA-39, and normalized to the levels of miRNA-93 that was determined with Norm Finder 
algorithm to be the least variable and therefore a suitable endogenous control (Fig. M1). In 
tissue samples and cell lines, RNU6-2 was considered as a housekeeping reference and used 
for normalization. Relative expression of miRNAs was calculated using the comparative 
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Figure M1. Selection of suitable housekeeping circulating miRNA. A, Stability analysis of 
tested miRNA in NormFinder. B, Ct values obtained by qRT-PCR of indicated miRNAs in 
randomly selected plasma samples from healthy samples (n=5) or chondrogenic tumor bearing 
patients (n=15). Boxes intersecting the dotted line and indicating low expression level were 
excluded from the analysis. 
 
For mRNA expression analysis, 1 µg of total RNA was transcribed to cDNA with a High-
Capacity cDNA Reverse Transcription Kit with RNAse Inhibitor (4374966, Applied 
Biosystems) as described in the protocol provided by the manufacturer. The cDNA was 
diluted in nuclease-free water and real-time qPCR was conducted on cDNA equivalent to 10 
ng of starting RNA with the Power SYBR Green PCR Master Mix (4367659, Applied 
Biosystems) on a StepOne-Plus Real-Time PCR System (Applied Biosystems). The 
denaturation was performed for 10 minutes at 95°C followed by 40 PCR cycles for 15 seconds 
at 95°C and for 1 minute at 60°C. The analysis was done with StepOne Software version 2.1 
(Applied Biosystems). Relative expression levels were calculated by the comparative (ΔΔCT) 
109 
 
method and normalized to GAPDH. All primers used are listed in Supplementary Table S4. 
The experiments were done in triplicates and repeated three times. 
 
Immunoblot antibodies 
Antibodies used were anti-FSCN1 (sc-46675, dilution 1:1500) obtained from Santa Cruz 
Biotechnology, anti-β-actin (MAB1501, dilution 1:10000) from Merck Millipore, and anti-
GAPDH (G9545, Sigma-Aldrich). HRP-conjugated secondary antibodies (sc-2054, sc-2055, 
dilution 1:3000) were purchased from Santa Cruz Biotechnologies. 
Soft-agar colony formation assay 
The experiments were carried out in 6-well cell culture plates containing 1.5 ml/well of 0.5% 
DNA grade agarose (V3121, Promega, base agar) in cell culture medium. Single cell 
suspensions (2x 104 or 1x104 cells per well for SW1353 or JJ012 derived cell lines, 
respectively) were prepared in 1.5 ml/well cell culture medium containing 0.35% agarose (top 
agar),seeded on the base agar and incubated in a humidified atmosphere of 95% air and 5% 
CO2 at 37°C. Twenty-four hours later 1.5 ml/well of cell culture medium (supplemented with 
doxocycline 1µg/mL and PSA 1X) was added. Cells were cultured for 3 weeks and the 
medium was exchanged in 3-4 day intervals. Colonies were stained with 0.005% crystal violet. 
Images of entire wells or random fields (10x magnification) were taken with a Nikon Eclipse 
E600 microscope (Nikon Corporation) and the numbers of colonies were counted with the 
image processing program ImageJ (http://rsb.info.nih.gov/ij/). The results are presented as the 
mean ± SEM of three independent experiments. 
Adhesion assay 
Adhesion assays were carried out in 96-well plates. The wells were coated with 15 µg/ml per 
well of collagen I (C3867, Sigma) or fibronectin (F2006, Sigma Aldrich), yielding 5 µg/cm2 of 
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substrate per well and incubated for 1 hour at room temperature (RT). After washing with 
PBS, the wells were blocked with heat-denatured (HD) 1% BSA in PBS for 1 hour at RT. 
Wells coated with HD-BSA alone were used as controls. Cells were detached with accutase 
(Sigma-Aldrich), resuspended in cell culture medium and 5 x 103 cells in 100 µl were seeded 
in triplicates into wells and allowed to adhere for 10 minutes at RT. Non-adherent cells were 
removed by washing with PBS and adherent cells were fixed with 10% formalin in PBS for 15 
minutes at RT and then stained with 0.05% crystal violet in H2O for 15 minutes at RT. Images 
of randomly selected areas of 3.6 mm2 were taken with an AxioCam MRm camera connected 
to the Zeiss Observer.Z1 inverted microscope (Carl Zeiss MicroImaging GmbH) set at 4x 
magnification. The number of adherent cells in the analyzed area was determined with ImageJ 
software (http://rsb.info.nih.gov/ij/) and the total number of adherent cells per well was then 
calculated. The percentage of adherent cells presented in the graphs was calculated from the 
total number of adherent cells per well divided by the total number of seeded cells and 
multiplied by 100. The data of three independent experiments done in triplicates are presented. 
Luciferase activity assay 
The 3′UTR fragments of selected genes were amplified by PCR from JJ012 genomic DNA 
using high fidelity Pfu DNA Polymerase (M774A, Promega) according to manufacturer’s 
protocol. The primers were the following: FSCN1 Fw: 
ATACTCGAGCAACCCTCCCTGCTAAC; FSCN1 Rev: 
GTCTCTAGACGCTATTTCCAGTTTGA. Of note, the primers contained XhoI and XbaI 
restriction sites for subsequent cloning strategy.  
The PCR products were cloned into a pGEM®-T Easy Vector (Promega), and then subcloned 
into a pmirGLO Dual-Luciferase miRNA Target Expression Vector (E1330, Promega), 
downstream of the firefly luciferase open reading frame (ORF). Mutagenesis of the miR-143 
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and miR-145 seed motifs in the 3′ UTR of selected genes was performed using the Q5® Site-
Directed Mutagenesis Kit (E0554S, New England Biolabs). Primer sequences are specified in 
Supplementary Table S5. Wild-type and mutated DNA sequences were verified by sequencing 
(Microsynth). DNA constructs were transfected to 5 x 103 HEK 293T or JJ012 cells in 96-
well plates together with miRNA mimics using Lipofectamine 2000 (11668027, 
ThermoFischer) according to the manufacturer's instructions. Final amounts of DNA and 
miRNA mimics were 200 ng/well and 30 nM, respectively. Activity of Firefly and Renilla 
luciferase enzymes was measured using Dual-Luciferase Reporter Assay System (E1910, 














6 Conclusion and Outlook 
Chondrosarcoma is a malignant tumor that can arise from preexisting benign chondrogenic 
neoplasms with a dismal prognosis. The current and preferred protocol for chondrosarcoma 
treatment is wide surgical excision of tumors as neither chemo- nor radiotherapeutics regimes 
have shown a clinical benefit for patients during the last decades. Therefore, for those many 
cases where chondrosarcoma tumors recur, develop metastases or cannot be removed, the 
treatment options are extremely limited. On top of this concern, there is a big gap of 
knowledge regarding the genetic events that are required for chondrosarcoma tumors to 
develop and progress. Ergo, biomarkers for the early detection and accurate categorization of 
chondrogenic tumors are very much needed. This has a profound clinical impact, since it is 
extremely difficult for oncopathologists to accurately determine correct specific tumor 
subtypes (for example, enchondromas vs chondrosarcomas Grade 1), which would require 
different clinical interventions. Thus, there is an urgent need for the development of targeted 
therapies and reliable biomarkers, which can potentially be translated into a better clinical 
management of chondrosarcoma. 
Consequently, the main interest of this thesis was set on identifying miRNAs (and the 
targets they regulate) that contribute to chondrosarcoma pathogenesis. As we wanted our 
research to be clinically –and potentially translationally- relevant, we did the initial 
identification of deregulated miRNAs from a cohort of tumors that included human 
chondrosarcoma specimens of different grades as well as benign chondrogenic tumors that are 
known to progress to chondrosarcoma (namely, enchondromas and osteochondromas).  
The data from the studies carried out provide solid evidence for the aberrant 
downregulation of the miRNA cluster miR-143/145 in chondrosarcoma, whose levels 
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inversely correlates with tumor aggressiveness. Our studies demonstrate that miR-143/145 
plays a key tumor suppressor role in chondrosarcoma by affecting various phenotypic features 
that contribute to cancer aggressiveness, namely adhesion to ECM substrates, anchorage-
independent growth and cell cycle. This behavior was reflected in the tumor growth inhibition 
upon miR-143/145 upregulation in a paratibial mouse orthotopic xenograft model, which was 
previously established as a sub-aim of the present thesis. Importantly, the direct gene target of 
both cluster members, FSCN1, is being affected from the miR-143/145 deregulation by 
showing significantly increased expression levels in more advanced chondrosarcoma tumors. 
The role of FSCN1 has been poorly described in the field of bone sarcomas and ours is the 
first piece of data demonstrating its relevance in chondrosarcoma. Moreover, our data from 
loss-of-function studies provide strong evidence that FSCN1 contributes to chondrosarcoma 
malignancy, underlying the miR-143/145:FSCN1 axis as an attractive and novel target for the 
development of therapies. Of note, the functional link between FSCN1 and miR-143/145 is 
currently being tested in combinatorial experiments as part of the revision process of the 
manuscript (Results 5.2)  
Future studies should consider the biological role of FSCN1 in in vivo settings in order to 
assess the potential role of this gene in primary tumor growth and/or metastatic disease in 
chondrosarcoma. In other epithelial cancer types, FSCN1 upregulation has been found to be 
clinically relevant (Yoder, Tso et al. 2005; Vignjevic, Schoumacher et al. 2007; Hashimoto, 
Kim et al. 2011).  Importantly, in vivo studies have shown that FSCN1 gene-knockout mice 
are normal (Yamakita, Matsumura et al. 2009). Over the past years, few FSCN1 inhibitors 
have been developed and evaluated in breast tumor models (Chen, Yang et al. 2010; Han, 
Huang et al. 2016). These small molecules were shown to block acting binding/bundling 
activities of FSCN1 resulting in reduced tumor cell migration rates and metastatic spread in 
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vivo. Very importantly, one of these drugs (NP-G2-044) will be tested in a Phase I study to 
determine the safety of the drug when given orally in patient with advanced or metastatic solid 
tumors (NCT03199586, recruiting patients).  
A substantial amount of the work presented in this thesis was focused on testing the 
potential use of circulating miRNAs as non-invasive biomarkers in chondrosarcoma. Our data 
provides strong proof that circulating miRNAs can be valuable tools for the improvement of 
the actual dismal diagnosis of chondrosarcoma and chondrogenic tumors. Our work 
demonstrates that miR-143/145 levels in plasma are tumor-malignancy dependent and, similar 
to what was observed in tumor samples, circulating miR-143/145 levels are lower in plasma of 
patients with more aggressive chondrosarcoma tumors. Moreover, circulating miR-145 was 
shown to be powerful for the distinction of benign versus malignant chondrogenic tumors. We 
believe that by combining multiple miRNAs into one signature, it could be possible to 
increase the sensitivity of our one-miRNA biomarker approach (miR-145) and lead to more 
accurate and earlier tumor detection and diagnosis, potentially leading to curative treatments 
and longer survival of chondrosarcoma patients. Additionally, aiming to increase the accuracy 
of tumor subtype diagnosis, circulating miRNA approaches can be combined with different 
imaging modalities in a multi-variable protocol, as it has been already implemented for other 
diseases (Nasser, Ranade et al. 2009; Regev, Healy et al. 2017).  
We believe that future efforts focused on the elucidation of the mechanisms governing 
miR-143/145 regulation in chondrosarcoma can be a valuable step towards understanding at 
which stage of the disease the deregulation occurs and which factors control it. It has been 
previously shown in other cancer models that miR-143/145 expression is regulated 
transcriptionally and post-transcriptionally by multiple mechanisms (Zeinali, Mansoori et al. 
2019). Furthermore, we believe that the global-miRNA signature generated by Next-
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Generation sequencing in this thesis constitutes a valuable source for the identification of 
additional novel miRNA candidates that may contribute to chondrosarcoma progression. Our 
data also includes a list of upregulated miRNA candidates that, to this date, have been sparsely 
investigated in the field of chondrosarcoma and should be addressed in future studies. 
Interestingly, over-expressed miRNAs can be silenced in vivo by antagomirs - chemically 
engineered oligonucleotides that are complementary to miRNAs-  opening up the possibility to 
test novel therapeutic approaches  in chondrosarcoma (Krutzfeldt, Rajewsky et al. 2005).  
 Taken together, based on the results presented in this thesis it can be concluded that the 
miR-143/145 cluster serves as a potent tumor-suppressor in chondrosarcoma. Both miRNAs 
exert their antitumor functions, at least in part, through a coordinated regulation of FSCN1 that 
we subsequently recognized as a malignancy promoting factor in chondrosarcoma 
pathogenesis. This work suggests that FSCN1 inhibition or miR-143/145 restoration may hold 
potential as novel therapeutic approaches to chondrosarcoma. Moreover, we newly identified 
circulating miR-145 as a promising non-invasive biomarker, and its use in combination with 
other miRNAs or with chondrosarcoma histopathological or imaging features holds promise 
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